tolterodine tartrate profile

Tolterodine Tartrate: An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	25137865
CHEBI ID	32245
MeSH ID	M0386986

Synonym
2-[(1r)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol (2r,3r)-2,3-dihydroxybutanedioic acid hydrate
(r)-2-(3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-methylphenol (r-(r,r))-2,3-dihydroxybutanedioate (1:1)(salt)
CHEBI:32245 ,
tolterodine tartrate
(2s,3s)-1,4-dihydroxy-1,4-dioxobutane-2,3-diolate;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol;hydron

Excerpt	Reference	Relevance
" Tolterodine was safe and generally well tolerated."	( Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. Höfner, K; Holmdahl, TH; Jonas, U; Madersbacher, H, 1997)	0.3
" Safety and tolerability were assessed from adverse events and laboratory measures."	( Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Appell, RA, 1997)	0.3
" Tolterodine at doses of 1 mg and 2 mg were tolerated significantly better than oxybutynin when adverse events, dry mouth (both frequency and intensity), dose reductions, and patient withdrawals were considered."	( Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Appell, RA, 1997)	0.3
" Patients receiving tolterodine should not experience these limitations and instead will get safe and long-term effective treatment for their condition."	( Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Appell, RA, 1997)	0.3
" The incidence of adverse events (mainly mild or moderate antimuscarinic effects) was comparable with placebo at tolterodine dosages of < or = 2 mg."	( Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Abrams, P; Cardozo, L; Fall, M; Nelson, E; Rentzhog, L; Stanton, SL, 1998)	0.3
"We evaluated the efficacy, patient acceptability and side effect profile of tolterodine, a new antimuscarinic agent for treating bladder overactivity."	( Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Clarke, B; Davis, BE; Dwyer, P; Millard, R; Moore, K; Susset, J; Tuttle, J, 1999)	0.3
" There was no clinical or electrocardiographic evidence of significant cardiac adverse events."	( Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Clarke, B; Davis, BE; Dwyer, P; Millard, R; Moore, K; Susset, J; Tuttle, J, 1999)	0.3
" The incidence of adverse events (mainly mild or moderate antimuscarinic effects) was comparable between placebo and tolterodine dosages of 2 mg twice daily."	( Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Hallén, B; Larsson, G; Nilvebrant, L, 1999)	0.3
" Tolterodine was significantly better tolerated than oxybutynin when adverse events (particularly frequency and intensity of dry mouth), dose reduction and patient withdrawals were considered."	( Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Appell, RA; Drutz, HP; Gleason, D; Klimberg, I; Radomski, S, 1999)	0.3
"Safety and tolerability were evaluated through spontaneously reported adverse events, electrocardiogram, and blood pressure measurements."	( Tolterodine: a safe and effective treatment for older patients with overactive bladder. Malone-Lee, JG; Maugourd, MF; Walsh, JB, 2001)	0.31
" Neither dosage of tolterodine was associated with serious drug-related adverse events during the study."	( Tolterodine: a safe and effective treatment for older patients with overactive bladder. Malone-Lee, JG; Maugourd, MF; Walsh, JB, 2001)	0.31
"Tolterodine (taken for 4 weeks) is safe and shows efficacy, particularly at a dosage of 2 mg bid, in the treatment of older patients with urinary symptoms attributable to overactive bladder."	( Tolterodine: a safe and effective treatment for older patients with overactive bladder. Malone-Lee, JG; Maugourd, MF; Walsh, JB, 2001)	0.31
" However such drugs are associated with a high incidence of anticholinergic adverse effects."	( Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Layton, D; Pearce, GL; Shakir, SA, 2001)	0.31
"The most common adverse events reported were dry mouth, headache, malaise, constipation, dyspepsia, nausea and vomiting and pain in abdomen."	( Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Layton, D; Pearce, GL; Shakir, SA, 2001)	0.31
" Dry mouth (of any severity) was the most common adverse event in both the tolterodine ER and placebo treatment arms, irrespective of age (<65: ER 22."	( Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Mattiasson, A; Stanton, SL; Zinner, NR, 2002)	0.31
" Tolterodine ER was safe and well tolerated."	( Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Jonas, U; Kreder, K; Mayne, C, 2002)	0.31
"To determine whether women with urinary incontinence (UI) can identify their allocation in a randomized controlled trial (RCT) of tolterodine (TOL), and whether correct identification is associated with outcomes and adverse effects (AEs)."	( "Unblinding" in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. DuBeau, CE; Khullar, V; Versi, E, 2005)	0.33
" Tolterodine ER was well tolerated and the most common adverse event was dry mouth (33."	( Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Homma, Y; Takei, M, 2005)	0.33
" There were no significant between-group differences in the incidence of adverse events."	( Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. Abrams, P; De Koning Gans, HJ; Kaplan, S; Millard, R, 2006)	0.33
" The incidence of adverse events (AEs) was similar in the three treatment groups (extended-release oxybutynin, 70%; extended-release tolterodine, 64%; and immediate-release tolterodine, 79%)."	( Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Armstrong, RB; Dmochowski, RR; Macdiarmid, S; Sand, PK, 2007)	0.34
"The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50."	( Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Li, HZ; Wang, W; Xiao, H; Yang, Y; Zhang, X; Zhang, Y; Zhao, XF, 2007)	0.34
" The incidence of adverse effects in the combination group was higher than that in the terazosin group."	( Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Li, HZ; Wang, W; Xiao, H; Yang, Y; Zhang, X; Zhang, Y; Zhao, XF, 2007)	0.34
" This study, although short term and limited numbers of patients, provides evidence that the combined therapy with terazosin plus tolterodine is a good approach for meeting the objectives of rapid, sustained, and safe improvements in the LUTS associated with BPH."	( Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Li, HZ; Wang, W; Xiao, H; Yang, Y; Zhang, X; Zhang, Y; Zhao, XF, 2007)	0.34
" Tamsulosin OCAS was well tolerated and the proportion of women discontinuing because of adverse events was low (4."	( A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. Bolodeoku, J; Cardozo, L; Robinson, D; Terpstra, G, 2007)	0.34
" Evaluation was by subjective assessment, visual analog scale, urodynamic assessment and adverse drug reaction monitoring."	( Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities. Kaur, B; Mahanta, K; Medhi, B; Narasimhan, KL, 2008)	0.35
" No adverse effects of hyperpyrexia, flushing or intolerance to outdoor temperatures, or dryness of mouth were observed in either group."	( Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities. Kaur, B; Mahanta, K; Medhi, B; Narasimhan, KL, 2008)	0.35
" Seven treatment-related adverse events were reported."	( Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. Borgstein, NG; Ellsworth, PI; Nijman, RJ; Reddy, PP, 2008)	0.35
")), adverse events, and retention."	( Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Chung, DE; Kaplan, SA; Staskin, DR; Te, AE, 2010)	0.36
" Treatments were generally well tolerated; discontinuation rates due to adverse events were 4%, 2%, 5%, 0%, and 1% with standard- and low-dose pregabalin/tolterodine ER, pregabalin, tolterodine ER, and placebo, respectively."	( Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder. Cossons, NH; Darekar, A; Marencak, J; Mills, IW, 2011)	0.37
" The incidence of adverse events in the tolterodine-treated group (28%) was significantly lower than that in the oxybutnin-treated group (57%) (P<0."	( [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. Chen, CJ; Deng, YJ; Ge, Z; Guo, YF; Lu, RG; Ma, G; Wang, LX; Zhu, HB, 2011)	0.37
" Adverse events and changes of urodynamic values and clinical data were compared between the solifenacin and tolterodine groups."	( Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY; Yu, HJ, 2011)	0.37
"Both solifenacin and tolterodine had similar urodynamic effects, therapeutic efficacy and adverse events in treating women with overactive bladder syndrome; however, tolterodine had a greater effect in increasing heart rate than solifenacin."	( Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY; Yu, HJ, 2011)	0.37
" The AMs used to treat OAB differ in their pharmacological profiles, which may affect their potential for causing adverse effects (AEs)."	( Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL, 2012)	0.38
"The incidence rates of overall adverse event, dry mouth, constipation and blurred vision of the experimental group (solifenacin 5 mg once per day) was 26."	( [Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis]. Jiang, XZ; Xu, C; Xu, ZS; Zhang, NZ; Zhao, HF, 2012)	0.38
"Dry mouth is the most common adverse event of solifenacin (5 mg once per day) and tolterodine (2 mg twice per day)."	( [Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis]. Jiang, XZ; Xu, C; Xu, ZS; Zhang, NZ; Zhao, HF, 2012)	0.38
" The safety analysis included adverse event (AE) reporting, laboratory assessments, ECG, postvoid residual volume and vital signs (blood pressure, pulse rate)."	( Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Angulo, JC; Blauwet, MB; Cambronero, J; Dorrepaal, C; Herschorn, S; Khullar, V; Martin, NE; Nitti, VW; Siddiqui, E; van Kerrebroeck, P, 2013)	0.39
" The incidence of adverse events was 54."	( Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome. Abrams, P; Andersson, KE; Chapple, CR; Deacon, S; Kuwayama, T; Masuda, T; Radziszewski, P; Small, M, 2014)	0.4
" The combination was well tolerated, and the adverse effects observed were consistent with the known safety profiles of tolterodine and pilocarpine."	( Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder. Dmochowski, RR; Duchin, K; Paborji, M; Staskin, DR; Tremblay, TM, 2014)	0.4
"9%, 12/308) were the most frequent adverse events."	( Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. Arumi, D; Cardozo, L; Carlsson, M; Crook, TJ; Grenabo, L; Herschorn, S; Kaplan, SA; Ntanios, F; Scholfield, D; Whelan, L, 2014)	0.4
" Both solifenacin and tolterodine ER have similar therapeutic efficacies and adverse events."	( [Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes]. Li, J; Li, P; Liu, B; Wang, Y; Wu, Y, 2014)	0.4
" Adverse events (AEs) were not increased with treatment progression."	( Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial. Cai, JL; Jing, S; Na, YQ; Yan, YF; Yang, Y; Zhou, Z, 2016)	0.43
" Safety assessments included treatment-emergent adverse events, vital signs, 12-lead electrocardiograms, post-void residual volume, and laboratory evaluations."	( Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M, 2019)	0.51
"1% women, mean age 65 years) experienced at least one treatment-emergent adverse event, with similar rates for all treatments."	( Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M, 2019)	0.51
" CV safety was assessed using treatment-emergent adverse events (TEAEs), vital signs, and 12-lead electrocardiograms (ECGs)."	( Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study. Hamada, T; Igawa, Y; Kato, D; Katoh, T; Kuroishi, K; Yamaguchi, O, 2020)	0.56
" Safety was evaluated using the proportion of treatment-emergent adverse events."	( Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Cardozo, L; Chapple, CR; Choudhury, N; Cruz, F; Heesakkers, J; Herschorn, S; Siddiqui, E; Staskin, D; Stoelzel, M, 2020)	0.56
" The primary outcome was safety, measured by incidence of adverse events."	( Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR). Frankel, J; Jankowich, R; Mudd, PN; Shortino, D; Staskin, D; Varano, S, 2021)	0.62
"4%) discontinued owing to adverse events."	( Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR). Frankel, J; Jankowich, R; Mudd, PN; Shortino, D; Staskin, D; Varano, S, 2021)	0.62
" Studies comparing one or more antimuscarinic drugs for treating OAB with reported adverse effects (AEs) were eligible."	( Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis. Wu, Q; Xu, F; Yang, N; Zhang, X, 2021)	0.62
"Clinical data on the use of overactive bladder (OAB) medications are limited by the physician interpretation of adverse effects rather than those that are patient reported."	( Adverse Events for Overactive Bladder Medications From a Public Federal Database. Bhojani, N; Chughtai, B; Drangsholt, S; Elterman, D; Sansone, S; Singh, Z; Stoddard, MD; Sze, C; Zorn, K, 2022)	0.72
" Food and Drug Administration Adverse Event Report System (FAERS) database was queried from 2004 to 2019."	( Adverse Events for Overactive Bladder Medications From a Public Federal Database. Bhojani, N; Chughtai, B; Drangsholt, S; Elterman, D; Sansone, S; Singh, Z; Stoddard, MD; Sze, C; Zorn, K, 2022)	0.72
" Aim of our study was to analyze real-life data of adverse events related to AMs and B3A reported on Eudra-Vigilance (EV) Database."	( Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database. Cicione, A; DE Nunzio, C; DI Giacomo, F; Disabato, G; Franco, A; Gallo, G; Gravina, C; Lombardo, R; Nacchia, A; Rovesti, L; Trucchi, A; Tubaro, A; Turchi, B, 2022)	0.72
"EV database is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA)."	( Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database. Cicione, A; DE Nunzio, C; DI Giacomo, F; Disabato, G; Franco, A; Gallo, G; Gravina, C; Lombardo, R; Nacchia, A; Rovesti, L; Trucchi, A; Tubaro, A; Turchi, B, 2022)	0.72
" Safety was assessed through adverse events (AEs)."	( Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial. Greene, H; Haag-Molkenteller, C; Newman, DK; Thomas, E; Varano, S, 2023)	0.91
"In this subgroup analysis, women receiving vibegron showed significant reductions in key efficacy end points versus placebo and favorable safety profile, consistent with the overall results from EMPOWUR, suggesting that vibegron is efficacious and safe for the treatment of OAB in this patient population."	( Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial. Greene, H; Haag-Molkenteller, C; Newman, DK; Thomas, E; Varano, S, 2023)	0.91

Excerpt	Reference	Relevance
"To determine whether cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of tolterodine by investigating potential differences in pharmacokinetics and pharmacodynamic (heart rate, accommodation, and salivation) of tolterodine and its 5-hydroxymethyl metabolite between poor metabolizers and extensive metabolizers of debrisoquin (INN, debrisoquine)."	( Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Alván, G; Bertilsson, L; Brynne, N; Dalén, P; Gabrielsson, J, 1998)	0.3
" The pharmacokinetics of tolterodine and 5-hydroxymethyl metabolite were determined, and the pharmacodynamic were measured."	( Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Alván, G; Bertilsson, L; Brynne, N; Dalén, P; Gabrielsson, J, 1998)	0.3
" The elimination of tolterodine from serum was rapid, with a half-life of less than 2 h in all species."	( Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. Kankaanranta, S; Påhlman, I; Palmér, L, 2001)	0.31
"The new ER formulation of tolterodine shows no pharmacokinetic interaction with food."	( Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. Olsson, B; Szamosi, J, 2001)	0.31
"The new once daily ER formulation of tolterodine 4mg shows pharmacokinetic equivalence (AUC24) to the existing IR tablet given at a dose of 2mg twice daily."	( Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Olsson, B; Szamosi, J, 2001)	0.31
" Pharmacokinetic assessments were performed on day 14 based on plasma levels of ethinyl estradiol and levonorgestrel up to 24 hours after dosing and serum tolterodine levels at 1 to 3 hours after dosing."	( The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Landgren, BM; Olsson, B, 2001)	0.31
" There was no evidence of a pharmacokinetic interaction between tolterodine and the steroid hormones in the oral contraceptive used, nor did the oral contraceptive show any relevant pharmacokinetic interaction with tolterodine."	( The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Landgren, BM; Olsson, B, 2001)	0.31
" These findings indicate that co-administration of tolterodine and warfarin is safe and well tolerated, with no clinically significant pharmacodynamic or kinetic interaction in healthy volunteers."	( Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. Hallén, B; Narang, P; Rahimy, M, 2002)	0.31
" The peak concentration ratios for oxybutynin and metabolite also conformed to this range; those for tolterodine did not."	( Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. Chen, A; Dmochowski, R; Gidwani, S; Gupta, S; MacDiarmid, S; Sathyan, G, 2005)	0.33
" The objective of this study was to establish the pharmacokinetic profile of fesoterodine and to highlight ist potential pharmacokinetic advantages over tolterodine."	( The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Malhotra, B; Simon, HU, 2009)	0.35
" Blood and urine samples for the analysis of 5-HMT were collected before and multiple times after drug administration for pharmacokinetic analysis."	( The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Malhotra, B; Simon, HU, 2009)	0.35
"The mean peak plasma concentration (Cmax) of 5-HMT and the mean area under the time versus concentration curve (AUC) increased proportionally with the fesoterodine dose."	( The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Malhotra, B; Simon, HU, 2009)	0.35
"This head-to-head study confirmed the findings of reduced pharmacokinetic variability of fesoterodine and further delineates that tolterodine, and not 5-HMT, was the principal source of variability after administration of tolterodine extended release."	( Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Crownover, P; Darsey, E; Fang, J; Glue, P; Malhotra, B, 2011)	0.37
" Saliva and plasma samples were collected for 3-5 half-life values of sitagliptin, cinacalcet, metformin, montelukast, tolterodine, hydrochlorothiazide (HCT), lornoxicam, azithromycin, diacerhein, rosuvastatin, cloxacillin, losartan and tamsulosin after oral dosing."	( Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. Arafat, T; Idkaidek, N, 2012)	0.38
" To confirm this effect in a clinical setting, we carried out a full pharmacokinetic study of a single oral dose of CYP2D6 substrate tolterodine in 30 healthy Korean individuals (HNF4α wild type: n = 24; HNF4α G60D heterozygotes: n = 6) who were pregenotyped for CYP2D6."	( Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals. Ghim, JL; Jiang, F; Kim, DH; Kim, EY; Kim, HS; Lee, SS; Oh, MK; Shin, JG; Shon, JH; Yeo, CW, 2013)	0.39
" This method was successfully applied to a pharmacokinetic study in humans."	( Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. Byeon, JY; Chae, WK; Jang, CG; Jung, EH; Kim, SH; Kim, YH; Lee, CM; Lee, SY; Lee, YJ, 2017)	0.46

Excerpt	Reference	Relevance
" Because older individuals typically take multiple medications, clinicians must pay special attention to potential drug-drug interactions that may cause adverse events or alter drug efficacy."	( Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. Chancellor, MB; de Miguel, F, 2007)	0.34
"To compare the efficacy of antimuscarinics alone versus antimuscarinics in combination with local oestrogens for OAB; to verify whether risk factors for lower antimuscarinic efficacy can be overcome by the concomitant use of local oestrogens."	( Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Bolis, P; Cardozo, L; Salvatore, S; Serati, M; Uccella, S, 2009)	0.35
"To assess the efficacy and safety of pregabalin alone or in combination with tolterodine extended release (ER) in subjects with idiopathic OAB."	( Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder. Cossons, NH; Darekar, A; Marencak, J; Mills, IW, 2011)	0.37
"To evaluate the efficacy and safety of Tolterodine Tartrate combined with the alpha-receptor blocker in the treatment of benign prostatic hyperplasia with detrusor overactivity (BPH-DO)."	( [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity]. Gan, W; Jia, HT; Li, YF; Luo, MH; Xie, S; Zhang, SF, 2011)	0.37
"A total of 113 patients with BPH-DO were randomly assigned to receive Tolterodine Tartrate combined with Cardura (Group A) and Cardura alone (Group B), both for 12 weeks."	( [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity]. Gan, W; Jia, HT; Li, YF; Luo, MH; Xie, S; Zhang, SF, 2011)	0.37
"To evaluate the therapeutic effect of Parkinson's disease combined with overactive bladder syndrome (GAB) treated with combined therapy of oral administration of Tolterodine with low dose and electroacuponcture."	( [Parkinson's disease combined with overactive bladder syndrome treated with acupuncture and medication]. Chen, YL; Feng, WJ; Zhang, XL, 2012)	0.38
"Sixty cases of Parkinson's disease combined with GAB were randomly divided into a combined acupuncture and medication group (group A) and a medication group (group B), 30 cases in each group."	( [Parkinson's disease combined with overactive bladder syndrome treated with acupuncture and medication]. Chen, YL; Feng, WJ; Zhang, XL, 2012)	0.38
"The therapeutic effect of Parkinson' s disease combined with GAB treated with combined therapy of Tolterodine with low dose and electroacupuncture is superior to that of complete dose of Tolterodine with oral administration, with less adverse reactions."	( [Parkinson's disease combined with overactive bladder syndrome treated with acupuncture and medication]. Chen, YL; Feng, WJ; Zhang, XL, 2012)	0.38
" Alpha blockers in combination with muscarinic receptor antagonists may have the potential to improve symptoms."	( A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia. Cao, Y; Chen, T; Guo, L; Niu, H; Wang, Y; Yang, X, 2016)	0.43

Excerpt	Reference	Relevance
" The absolute bioavailability was highly variable, ranging from 10 to 70%."	( Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Brynne, N; Edlund, PO; Gabrielsson, J; Hallén, B; Höglund, P; Palmér, L; Stahl, MM, 1997)	0.3
" Improvements in drug delivery systems have altered drug bioavailability and pharmacokinetics."	( Advancements in pharmacologic management of the overactive bladder. Appell, RA; Dmochowski, RR, 2000)	0.31
" Bioavailability varied between 2-20% in rodents and 58-63% in the dog."	( Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. Kankaanranta, S; Påhlman, I; Palmér, L, 2001)	0.31
"To determine whether food intake influences the pharmacokinetics of a new, once daily, extended release (ER) capsule formulation of tolterodine in healthy volunteers, and to compare its bioavailability with that of the existing immediate release (IR) tablet."	( Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. Olsson, B; Szamosi, J, 2001)	0.31
"No effect of food on the bioavailability of tolterodine ER capsules was apparent and there was no sign of dose-dumping with meals."	( Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. Olsson, B; Szamosi, J, 2001)	0.31
"TCl, a quaternary amine, exhibits high solubility in water but low oral bioavailability (9."	( Trospium chloride for the treatment of overactive bladder with urge incontinence. Machado, C; Singh-Franco, D; Tuteja, S; Zapantis, A, 2005)	0.33
"This study assessed the effect of the proton pump inhibitor omeprazole on the bioavailability of the extended-release formulations of oxybutynin and tolterodine."	( Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. Chen, A; Dmochowski, R; Gidwani, S; Gupta, S; MacDiarmid, S; Sathyan, G, 2005)	0.33
" The validated LC-ESI-MS method has been used successfully to study tolterodine tartrate pharmacokinetic, bioavailability and bioequivalence in 20 healthy male volunteers."	( High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma. Tian, Y; Xu, F; Zhang, B; Zhang, Z, 2005)	0.33
" A prodrug approach was necessary for systemic bioavailability of 5-HMT after oral administration."	( The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Gandelman, K; Malhotra, B; Michel, MC; Sachse, R; Wood, N, 2009)	0.35
" The data suggest that fesoterodine delivers 5-HMT consistently, regardless of CYP2D6 status, with up to 40% higher bioavailability compared with tolterodine."	( Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Crownover, P; Darsey, E; Fang, J; Glue, P; Malhotra, B, 2011)	0.37
"49 mg/L, and the absolute bioavailability was 27."	( Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. Chen, Y; Fang, L; Li, C; Liu, C; Liu, J; Mu, L; Sun, L; Wang, Z; Xi, H, 2012)	0.38
" The absolute bioavailability of tolterodine was 11."	( Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. Li, Y; Liu, X; Shi, Y; Sui, C; Sun, F; Wu, Y; Zhou, Y, 2013)	0.39
" In the pharmacokinetic studies, sustained-release over 24 h and absolute bioavailability of the hydrogels (24."	( Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. Dai, W; Fu, L; Li, Y; Liu, W; Liu, X; Sun, F; Teng, L; Wu, Y; Zhao, J, 2014)	0.4
"Relative bioavailability study of tolterodine in healthy human volunteers was done using saliva and plasma matrices in order to investigate the robustness of using saliva instead of plasma as a surrogate for bioavailability and bioequivalence of class III drugs according to the salivary excretion classification system (SECS)."	( Saliva versus Plasma Relative Bioavailability of Tolterodine in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System. Idkaidek, N; Najib, N; Najib, O; Salem, II, 2016)	0.43

Excerpt	Relevance	Reference
" Tolterodine, in the dosage used, was both objectively and subjectively shown to exert a marked inhibitory effect on micturition in healthy subjects, and the data suggest a more pronounced effect on bladder function than on salivation."	( Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Andersson, KE; Ekström, B; Mattiasson, A; Sparf, B; Stahl, MM, 1995)	0.29
" An optimal efficacy/side-effect profile is obtained with tolterodine, at a dosage of 1 or 2 mg twice daily, which seems to have less propensity to cause dry mouth than the currently available antimuscarinic drugs."	( Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Hallén, B; Larsson, G; Nilvebrant, L, 1997)	0.3
"To investigate the efficacy and safety of tolterodine, a new antimuscarinic agent, and define the optimum dosage in patients with symptoms of detrusor instability (urgency, increased frequency of micturition and/or urge incontinence)."	( Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Abrams, P; Cardozo, L; Fall, M; Nelson, E; Rentzhog, L; Stanton, SL, 1998)	0.3
" at a dosage of 2 mg twice daily, the frequency of micturition, episodes of incontinence and pad use were reduced by 20%, 46% and 29%, respectively, while the volume at first contraction increased by 89 mL."	( Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Abrams, P; Cardozo, L; Fall, M; Nelson, E; Rentzhog, L; Stanton, SL, 1998)	0.3
" The optimum dosage appears to be 1-2 mg twice daily."	( Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Abrams, P; Cardozo, L; Fall, M; Nelson, E; Rentzhog, L; Stanton, SL, 1998)	0.3
" Only minor differences in pharmacodynamic effects after tolterodine dosage were observed between the groups."	( Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Alván, G; Bertilsson, L; Brynne, N; Dalén, P; Gabrielsson, J, 1998)	0.3
" In order to assess the optimum dosage for use in future clinical studies, a double-blind, randomized, placebo-controlled, parallel-group, multicenter study was performed in 90 patients with detrusor hyperreflexia and symptoms of urinary urgency, frequency, and/or urge incontinence."	( Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Amarenco, G; Lock, MT; Madersbacher, HG; Messelink, EJ; Soler, JM; Thüroff, JW; Van Kerrebroeck, PE, 1998)	0.3
" Despite short terminal disposition half-lives of 2-3 and 3-4 hours for tolterodine and its active 5-hydroxy metabolite, respectively, twice/day dosing is effective due to the drug's prolonged pharmacodynamic effects."	( Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Guay, DR, 1999)	0.3
" A dosage of 4 mg twice daily was, however, associated with an increase in residual urinary volume."	( Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Hallén, B; Larsson, G; Nilvebrant, L, 1999)	0.3
" The optimal dosage is 1 to 2 mg twice daily, irrespective of metabolic phenotype."	( Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Hallén, B; Larsson, G; Nilvebrant, L, 1999)	0.3
" Drug dosage in the 20 patients who tolerated tolterodine was 1 mg bid in 3 and 2 mg bid in 17 (85%)."	( Tolterodine for overactive bladder: time to onset of action, preferred dosage, and 9-month follow-up. Atan, A; Chancellor, MB; Erickson, JR; Kim, DY; Konety, BR; Yokoyama, T, 1999)	0.3
" The adverse effect profiles of tolterodine and oxybutynin are similar; however, comparative clinical trials have shown significantly fewer patients taking tolterodine require dosage reductions or discontinue therapy due to antimuscarinic adverse effects such as dry mouth."	( Tolterodine use for symptoms of overactive bladder. Morgenstern, NE; Ruscin, JM, 1999)	0.3
" The warfarin dosage had remained constant for many weeks in both patients prior to and during the tolterodine trials."	( Tolterodine-warfarin drug interaction. Colucci, VJ; Rivey, MP, 1999)	0.3
" Similarly, the potential improvements in tolerability associated with different dosage formulations of oxybutynin, and the clinical utility of S-oxybutynin, are yet to be conclusively demonstrated."	( Muscarinic receptor antagonists in the treatment of overactive bladder. Chapple, CR, 2000)	0.31
" The distribution pattern after repeat oral dosing was similar to that after a single dose, although the decline in tissue concentrations was slower."	( Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice. d'Argy, R; Nilvebrant, L; Påhlman, I, 2001)	0.31
" The intestinal absorption of tolterodine after oral dosing was almost complete in all three species, with peak serum concentrations observed within 1 hour post-dose."	( Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. Kankaanranta, S; Påhlman, I; Palmér, L, 2001)	0.31
"There were no safety concerns in terms of the change in residual urinary volume for any of the three dosage groups; values were comparable with baseline after 2 weeks of treatment for all three dosages."	( The overactive bladder in children: a potential future indication for tolterodine. Hellström, AL; Hjälmås, K; Läckgren, G; Mogren, K; Stenberg, A, 2001)	0.31
" Dosage reduction occurred in 13% of patients."	( Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. Abrams, P; Appell, RA; Drutz, HP; Millard, R; Van Kerrebroeck, PE; Wein, A, 2001)	0.31
" Neither dosage of tolterodine was associated with serious drug-related adverse events during the study."	( Tolterodine: a safe and effective treatment for older patients with overactive bladder. Malone-Lee, JG; Maugourd, MF; Walsh, JB, 2001)	0.31
"Tolterodine (taken for 4 weeks) is safe and shows efficacy, particularly at a dosage of 2 mg bid, in the treatment of older patients with urinary symptoms attributable to overactive bladder."	( Tolterodine: a safe and effective treatment for older patients with overactive bladder. Malone-Lee, JG; Maugourd, MF; Walsh, JB, 2001)	0.31
" Dosage reduction to 1 mg twice daily was required in 23% of patients."	( Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Abrams, P; Jacquetin, B; Jonas, U; Malone-Lee, J; Tammela, T; Wein, A; Wyndaele, JJ, 2001)	0.31
" Pharmacokinetic assessments were performed on day 14 based on plasma levels of ethinyl estradiol and levonorgestrel up to 24 hours after dosing and serum tolterodine levels at 1 to 3 hours after dosing."	( The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Landgren, BM; Olsson, B, 2001)	0.31
" The convenience of once-daily dosing of antimuscarinic agents would be expected to improve patient compliance and further relieve the symptoms of OAB."	( Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Rovner, ES; Wein, AJ, 2002)	0.31
" Therefore, these results suggest that the normal dosage of tolterodine (2 mg twice daily) may have less effect on visual accommodation than the equivalent dosage of oxybutynin (5 mg three times daily) in patients with an overactive bladder."	( Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Chapple, CR; Nilvebrant, L, 2002)	0.31
" The dose was titrated until effective (onset of complete diurnal urinary continence), maximal recommended dosage was achieved or bothersome anticholinergic side effects developed."	( Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. Crocker, J; Reinberg, Y; Vandersteen, D; Wolpert, J, 2003)	0.32
" Peak plasma concentrations of oxybutynin and the major active metabolite, N-desethyloxybutynin, are reached 24 - 48 hours after a single application and therapeutic concentrations are maintained throughout the dosage interval."	( Transdermal oxybutynin: for overactive bladder. Bang, LM; Easthope, SE; Perry, CM, 2003)	0.32
" New antimuscarinic anticholinergic medications have improved the treatment of OAB, offering patients efficacy equal to that of immediate-release oxybutynin with fewer side effects and an improved dosing schedule."	( Overactive bladder: improving the efficacy of anticholinergics by dose escalation. MacDiarmid, SA, 2003)	0.32
"To evaluate the dose-response relationship and safety/tolerability of solifenacin succinate (YM905) in the treatment of overactive bladder (OAB), and to compare its efficacy and safety/tolerability with tolterodine 2 mg twice daily."	( Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. Araño, P; Bosch, JL; Chapple, CR; De Ridder, D; Kramer, AE; Ridder, AM, 2004)	0.32
"To assess in a phase 3a trial the efficacy of solifenacin succinate, a once-daily oral antimuscarinic agent in development at 5-mg and 10-mg dosage strengths, for the treatment of overactive bladder (OAB) (Yamanouchi Pharmaceutical Co."	( Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Al-Shukri, S; Chapple, CR; Everaert, K; Huang, M; Meffan, P; Rechberger, T; Ridder, A, 2004)	0.32
" The efficacy of oxybutynin chloride has been sufficiently proved; however its dosage and side effects, although scarce in children, usually cause treatment discontinuation."	( [Treatment of bladder instability (non-neurogenic hyperactive bladder) in children, with tolterodine]. Caffaratti Sfulcini, J; de la Peña, E; Garat Barredo, JM, 2004)	0.32
" These findings suggest that there should not be a need for routine adjustment of tolterodine dosage in the presence of duloxetine."	( Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. Chan, C; Gonzales, CR; Hua, TC; Knadler, MP; Pan, A; Poo, YK; Skinner, MH; Wise, SD, 2004)	0.32
" Clinically relevant drug interactions are limited to cytochrome P450 3A4 inhibitors, such as ketoconazole, and co-administration with such agents warrants a tolterodine dosage decrease."	( Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Burrows, L; Garely, AD, 2004)	0.32
" Tolterodine at the recommended dosage of 2 mg twice daily improves incontinence and bladder volumes compared with placebo, and without significant dry mouth."	( Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. Bard, RJ; Casey, AR; Ethans, KD; Nance, PW; Schryvers, OI, 2004)	0.32
" While trospium chloride dosage adjustments based on age or sex appear unwarranted, such adjustments may be needed in patients with severe renal impairment."	( Trospium chloride in the management of overactive bladder. Rovner, ES, 2004)	0.32
" This finding may be explained by a high placebo response and under dosage of tolterodine among children with greater body weight."	( Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. Borgstein, NG; Djurhuus, JC; Ellsworth, P; Nijman, RJ, 2005)	0.33
" Exploratory analyses also showed that children weighing 35 kg or less with detrusor overactivity characterized by incontinence and/or frequent voiding benefited most from tolterodine treatment, suggesting that a weight adjusted dosing regimen may be required for optimal response among older and heavier children."	( Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. Borgstein, NG; Djurhuus, JC; Ellsworth, P; Nijman, RJ, 2005)	0.33
"Solifenacin, with a flexible dosing regimen, showed greater efficacy to tolterodine in decreasing urgency episodes, incontinence, urge incontinence and pad usage and increasing the volume voided per micturition."	( A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Bolodeoku, J; Chapple, CR; Drogendijk, T; Martinez-Garcia, R; Selvaggi, L; Toozs-Hobson, P; Warnack, W; Wright, DM, 2005)	0.33
"Solifenacin, with a flexible dosing regimen, was found to be superior to tolterodine ER with respect to the majority of the efficacy variables."	( A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Bolodeoku, J; Chapple, CR; Drogendijk, T; Martinez-Garcia, R; Selvaggi, L; Toozs-Hobson, P; Warnack, W; Wright, DM, 2005)	0.33
" We urodynamically evaluated the dose and concentration effects of tolterodine to establish safe and effective dosing regimens."	( Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. Borgstein, NG; Ellsworth, PI; Nijman, RJ; Reddy, PP, 2005)	0.33
" PK was assessed after 8 weeks, urodynamic assessments were conducted after each 4-week dosing period and 3-day micturition diaries were completed."	( Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. Borgstein, NG; Ellsworth, PI; Nijman, RJ; Reddy, PP, 2005)	0.33
" In study 3 (11 patients) there were no obvious dose-response relationships."	( Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. Borgstein, NG; Ellsworth, PI; Nijman, RJ; Reddy, PP, 2005)	0.33
"These results support the safety of age and body weight adjusted dosing regimens for further clinical evaluation of tolterodine in children with neurogenic detrusor overactivity."	( Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. Borgstein, NG; Ellsworth, PI; Nijman, RJ; Reddy, PP, 2005)	0.33
" The antagonistic effect of oral tolterodine on the dose-response curves to pilocarpine was significantly weaker than that of oxybutynin."	( Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice. Maruyama, S; Oki, T; Takagi, Y; Yamada, S; Yamamura, HI, 2006)	0.33
"To evaluate the efficacy and tolerability of nighttime tolterodine dosing on urgency-related micturitions in patients with overactive bladder (OAB) and nocturia."	( Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Guan, Z; Rackley, R; Rovner, ES; Wang, JT; Weiss, JP, 2006)	0.33
" Adverse events associated with nighttime dosing of TER versus placebo were few."	( Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Guan, Z; Rackley, R; Rovner, ES; Wang, JT; Weiss, JP, 2006)	0.33
" Nighttime dosing with TER was associated with few adverse events and adverse event-related withdrawals."	( Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Guan, Z; Rackley, R; Rovner, ES; Wang, JT; Weiss, JP, 2006)	0.33
" On her next anticoagulation clinic visit, the patient's INR had increased, although the dosage of warfarin had been reduced when the tolterodine had been prescribed."	( Probable interaction between tolterodine and warfarin. Taylor, JR, 2006)	0.33
"The dosage of the antimuscarinic drugs: Tolterodine ER or Trospium was increased to a higher-than-recommended dosage in patients where the manufacturer's recommended dosage had failed."	( Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Aguilar, Y; Horstmann, M; Schaefer, T; Sievert, KD; Stenzl, A, 2006)	0.33
" If neurogenic detrusor overactivity continued and the medication was well tolerated, the dosage was doubled to either 8 mg of Tolterodine ER [2 x 4 mg (n = 11)] or 90 mg of Trospium [3 x 30 mg (n = 10)]."	( Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Aguilar, Y; Horstmann, M; Schaefer, T; Sievert, KD; Stenzl, A, 2006)	0.33
"The increased dosage of Tolterodine or Trospium is an effective treatment in patients with neurogenic bladder."	( Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Aguilar, Y; Horstmann, M; Schaefer, T; Sievert, KD; Stenzl, A, 2006)	0.33
"To evaluate the efficacy and safety of nighttime dosing with tolterodine extended release (TER) in men with overactive bladder (OAB) and nocturia."	( Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Dmochowski, R; Guan, Z; Kaplan, SA; Roehrborn, CG; Rovner, ES; Wang, JT, 2006)	0.33
"Nighttime TER dosing reduced urgency-related micturitions and was well tolerated in men with OAB and nocturia."	( Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Dmochowski, R; Guan, Z; Kaplan, SA; Roehrborn, CG; Rovner, ES; Wang, JT, 2006)	0.33
" It is a rare complication of therapy for overactive bladder and resolved when dosage was reduced to 1 mg, although overactive bladder symptoms were still controlled."	( Cognitive dysfunction with tolterodine use. Bolis, P; Cardozo, L; Salvatore, S; Serati, M; Uccella, S, 2007)	0.34
"To evaluate the efficacy of tamsulosin oral-controlled absorption system (OCAS) vs placebo in overactive bladder (OAB), to evaluate the safety and tolerability of once-daily dosing with tamsulosin OCAS, and to compare the efficacy and safety with tolterodine extended-release (ER)."	( A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. Bolodeoku, J; Cardozo, L; Robinson, D; Terpstra, G, 2007)	0.34
" This article summarizes the efficacy, contraindications, precautions, dosing and common side effects of these agents."	( Pharmacologic management of overactive bladder. Hilas, O; Lam, S, 2007)	0.34
"14]) but did not resolve urinary incontinence, with no significant dose-response association."	( Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Kane, RL; Shamliyan, TA; Wilt, TJ; Wyman, J, 2008)	0.35
"A 1-year Markov model was constructed using data from a 12-week, randomised, double-blind study that compared flexible dosing with solifenacin (5 mg and 10 mg) with tolterodine (IR 2 mg bd/ER 4 mg) in adults with OAB."	( A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Bolodeoku, J; Khullar, V; Mundy, A; Odeyemi, I; Speakman, M, 2008)	0.35
"Flexible dosing with solifenacin is likely to be cost-effective versus tolterodine in the treatment of OAB."	( A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Bolodeoku, J; Khullar, V; Mundy, A; Odeyemi, I; Speakman, M, 2008)	0.35
"Only patients with primary nocturnal enuresis refractory to the maximal dosage of desmopressin were enrolled."	( Combination therapy with desmopressin and an anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial. Austin, PF; Campigotto, MJ; Coplen, DE; Ferguson, G; Royer, ME; Yan, Y, 2008)	0.35
" Therefore, in contrast to tolterodine, no reduction of fesoterodine dosage is required under conditions of reduced elimination."	( The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Malhotra, B; Simon, HU, 2009)	0.35
"The purpose of the present analysis was to analyze and compare the cost-effectiveness of solifenacin flexible dosing (5-10 mg) with tolterodine 4 mg sustained release (SR) or placebo (assumed to be comparable to no treatment) for patients with overactive bladder (OAB) symptoms."	( Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Axelsen, S; Kulseng-Hansen, S; Mattiasson, A; Milsom, I; Nilsson, CG; Wickstrøm, J, 2009)	0.35
"Solifenacin flexible dosing was more effective with respect to reducing OAB symptoms compared to both placebo and tolterodine 4 mg."	( Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Axelsen, S; Kulseng-Hansen, S; Mattiasson, A; Milsom, I; Nilsson, CG; Wickstrøm, J, 2009)	0.35
"Solifenacin flexible dosing was a cost-effective treatment alternative compared to tolterodine 4 mg SR."	( Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Axelsen, S; Kulseng-Hansen, S; Mattiasson, A; Milsom, I; Nilsson, CG; Wickstrøm, J, 2009)	0.35
" Drug pharmacokinetics was studied after transdermal application to human volunteers compared to the commercial oral dosage form using a newly developed LC-MS/MS assay."	( Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. Elshafeey, AH; Fathallah, MM; Kamel, AO, 2009)	0.35
" At least partially due to the avoidance of variations in pharmacokinetic exposures observed with tolterodine, it was possible to develop fesoterodine with the flexibility of two efficacious and well-tolerated dosage regimens of 4 and 8 mg daily."	( The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Gandelman, K; Malhotra, B; Michel, MC; Sachse, R; Wood, N, 2009)	0.35
"In this large group of older patients, flexibly dosed solifenacin was associated with reductions in diary-documented OAB symptoms (VERSUS)."	( Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies. Capo', JP; Forero-Schwanhaeuser, S; He, W; Lucente, V, 2011)	0.37
" Therefore, the developed sustained-release tablet formulation of TOL could be an alternative dosage form to the SR capsule for treatment of OAB."	( Preparation and evaluation of once-daily sustained-release coated tablets of tolterodine-L-tartrate. Chang, SW; Kim, JO; Kim, YI; Pradhan, R, 2014)	0.4
"We aimed to clarify the impact of night-time dosing with tolterodine extended release (ER) on nocturia."	( Tolterodine treatment of women with overactive bladder syndrome: Comparison of night-time and daytime dosing for nocturia. Hsiao, SM; Lin, HH; Tsai, KH, 2017)	0.46
" Thirty-six patients were in the daytime dosing group, and the other 36 patients were in the night-time dosing group."	( Tolterodine treatment of women with overactive bladder syndrome: Comparison of night-time and daytime dosing for nocturia. Hsiao, SM; Lin, HH; Tsai, KH, 2017)	0.46
"Night-time dosing of tolterodine ER may benefit female patients suffering from nocturia due to a greater voided volume per micturition at midnight."	( Tolterodine treatment of women with overactive bladder syndrome: Comparison of night-time and daytime dosing for nocturia. Hsiao, SM; Lin, HH; Tsai, KH, 2017)	0.46
" Tolterodine ER was dosed at 4 mg for 8 weeks and mirabegron was dosed at 25 mg for 4 weeks then increased to 50 mg for the next 4 weeks."	( Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Fialkov, J; Gooch, K; Herschorn, S; Schermer, CR; Staskin, D; Tu, LM; Walsh, T, 2018)	0.48
"To study the dosage regimen of oral M-receptor blocker following transurethral resection of the prostate (TURP) for severe benign prostate hyperplasia (BPH) with predominant urine storage period symptoms (USPSs) and its clinical effect."	( [A dosage regimen of M-receptor blocker after TURP for severe BPH with predominant urine storage symptoms]. Cai, JL; Chen, D; Han, JC; Li, NC; Na, YQ; Song, YF; Xia, M; Xiao, JT, 2017)	0.46
"Four to eight weeks of oral administration of M-receptor blocker may be an effective dosage regimen for severe BPH with predominant USPSs after TURP."	( [A dosage regimen of M-receptor blocker after TURP for severe BPH with predominant urine storage symptoms]. Cai, JL; Chen, D; Han, JC; Li, NC; Na, YQ; Song, YF; Xia, M; Xiao, JT, 2017)	0.46

Class	Description
tartrate salt	A salt of the organic compound tartaric acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	36 (5.29)	18.2507
2000's	375 (55.07)	29.6817
2010's	229 (33.63)	24.3611
2020's	41 (6.02)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	258 (36.34%)	5.53%
Reviews	106 (14.93%)	6.00%
Case Studies	17 (2.39%)	4.05%
Observational	6 (0.85%)	0.25%
Other	323 (45.49%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (89)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT01291316]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2010-04-30	Completed
Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain [NCT01179828]	Phase 3	150 participants (Actual)	Interventional	2010-07-31	Completed
International, Multicenter, Open-label, Randomized, Comparative Clinical Study of Efficiency and Safety of Medicinal Product Uritos® (Imidafenacin, Film-coated Tablets; 0,1 mg, Kyorin Pharmaceutical Co. Ltd, Japan) and Urotol® (Tolterodine, Film-coated Ta [NCT03575702]	Phase 3	300 participants (Actual)	Interventional	2016-07-18	Completed
STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study [NCT01181505]	Phase 1	31 participants (Actual)	Interventional	2007-01-31	Completed
An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder [NCT03492281]	Phase 3	1,530 participants (Actual)	Interventional	2018-03-26	Completed
Effect of Combined Use of Tolterodine and Continuous Positive Airway Pressure vs Continuous Positive Airway Pressure Only Treatment on Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome: A Randomized Clinical Tri [NCT05250245]	Phase 4	60 participants (Actual)	Interventional	2020-06-01	Completed
Double Blind Exploratory Three Arm Randomized Trial to Evaluate the Safety and Efficacy of Herbal Preparation 'Herbmed Plus' in Ureteral Stent Discomfort [NCT01356355]	Phase 2	140 participants (Actual)	Interventional	2012-04-30	Completed
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania [NCT03602508]		5,589 participants (Actual)	Observational	2018-07-20	Completed
[NCT01282840]		676 participants (Actual)	Interventional	2010-07-20	Completed
Behavior Enhances Drug Reduction of Incontinence [NCT00090584]		307 participants (Actual)	Interventional	2004-08-31	Completed
An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder [NCT03583372]	Phase 3	506 participants (Actual)	Interventional	2018-06-14	Completed
Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study [NCT05946902]	Phase 4	150 participants (Anticipated)	Interventional	2023-09-12	Recruiting
Efficacy Comparison Between Different Management Strategies for Consistent Overactive Bladder (OAB) in Patients With Spinal Vascular Malformations After Surgery [NCT03280316]		100 participants (Anticipated)	Interventional	2023-01-31	Not yet recruiting
Effects of Amitriptyline on Central Pain Processing in Healthy Volunteers Depending on CYP Pharmacogenetics [NCT02256956]	Phase 4	48 participants (Actual)	Interventional	2014-11-30	Completed
A Placebo Controlled Randomized, 12-week, Dose-ranging, Double-blind Study Versus Placebo Using Tolterodine as a Study Calibrator, to Evaluate Efficacy and Safety of SSR240600C in Women With Overactive Bladder Including Urge Urinary Incontinence [NCT00564226]	Phase 2	345 participants (Actual)	Interventional	2007-11-30	Completed
A Double Blind, Randomized Placebo Controlled Trial of the Perioperative Use of Solifenacin in the Management of Postoperative Overactive Bladder Symptoms in Patients With Mixed Incontinence Undergoing Suburethral Sling Procedures. [NCT00852696]		1 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to Investigator left Cleveland Clinic and absolutely no data is available.)
A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder A 52-week Extension to: A Phase IIb Randomized, Placebo- and Active Comparator [NCT01314872]	Phase 2	1,395 participants (Actual)	Interventional	2011-03-31	Completed
A Randomised, Multi-Centre, Double-Blind, Placebo and Active-Controlled, 5-Way Parallel Group Study to Investigate the Efficacy, Safety and Tolerability of ONO-8539 in Patients With Overactive Bladder [NCT00876421]	Phase 2	435 participants (Actual)	Interventional	2009-04-30	Completed
Low Dose Tadalafil 5mg for Treatment of Female Overactive Bladder Syndrome :6 Months Follow up [NCT04500860]	Phase 1	90 participants (Actual)	Interventional	2020-12-01	Completed
A Prospective, Non-interventional, Registry Study of Patients Initiating Pharmacologic Therapy for Overactive Bladder in Taiwan, Korea and China [NCT03572231]		805 participants (Actual)	Observational	2018-07-19	Completed
Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics [NCT04090190]	Phase 4	20 participants (Actual)	Interventional	2019-10-30	Completed
Effects of Amitriptyline on Central Pain Processing in Healthy Volunteers Depending on CYP Pharmacogenetics [NCT02256943]	Phase 4	48 participants (Actual)	Interventional	2014-11-30	Completed
Exploring Predictors of Symptoms Relapse After Discontinuation of Successful Treatment With a Tolterodine Prolonged Release Capsules (4 mg, Once Daily) in Overactive Bladder Patients: A Prospective Randomized Multicenter Trial [NCT00730535]	Phase 4	173 participants (Actual)	Interventional	2006-08-31	Completed
A Phase 2, 26 Week, Multicentre, Randomized Double Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Tolterodine, Pregabalin and a Tolterodine-Pregabalin Combination for Idiopathic Overactive Bladder [NCT00746681]	Phase 2	188 participants (Actual)	Interventional	2005-12-31	Completed
Solifenacin in a Flexible Dose Regimen With Tolterodine as an Active Comparator in a Double-blind, Double-dummy, Randomised Overactive Bladder Symptom Trial [NCT00802373]	Phase 3	1,355 participants (Actual)	Interventional	2003-07-31	Completed
Double-Blind Crossover Comparative Ambulatory Urodynamic Monitoring (AUM) Study of Tolterodine PR and Propiverine in Korean Patients With Overactive Bladder (OAB) [NCT00646880]	Phase 3	41 participants (Actual)	Interventional	2003-03-31	Completed
Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder (Phase Ⅳ) [NCT00836381]	Phase 4	56 participants (Actual)	Interventional	2009-02-28	Completed
Effects of THVD-201 on Pharmacokinetics and Pharmacodynamics of Tolterodine in Healthy Subjects [NCT01036035]	Phase 1	18 participants (Actual)	Interventional	2009-09-30	Completed
Effects of Gaba-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers [NCT01011036]	Phase 3	17 participants (Actual)	Interventional	2009-12-31	Completed
Randomized Controlled Trial of Tolterodine in Combination With or Without Low-Dose Intravaginal Estradiol Cream for the Treatment of Overactive Bladder in Post-Menopausal Women [NCT00465894]		58 participants (Actual)	Interventional	2007-04-30	Completed
A 3-way Cross-over, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess Pharmacologic Effects of a 7-day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d. on Cardiovascular Parameters in Healthy Subjects 50 Years of Age [NCT00703703]	Phase 1	117 participants (Actual)	Interventional	2008-05-31	Completed
Symptom Specific Effectiveness of Tolterodine ER 4 mg in Patients With Symptoms of Overactive Bladder (OAB) in a Primary Care Setting. A Phase IV, Open-label, Single-arm, Non-randomized, Trial in Adult Patients With OAB. [NCT00645281]	Phase 4	896 participants (Actual)	Interventional	2004-03-31	Completed
A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder [NCT00689104]	Phase 3	2,336 participants (Actual)	Interventional	2008-04-28	Completed
The Clinical Efficacy of Pelvic Organ Prolapse Surgery [NCT02599311]	Phase 3	1,000 participants (Anticipated)	Interventional	2015-08-31	Recruiting
Special Investigation For Long Term Use Of Detrusitol (Regulatory Post Marketing Commitment Plan). [NCT00795509]		374 participants (Actual)	Observational	2007-08-31	Completed
12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB) [NCT00444925]	Phase 3	1,712 participants (Actual)	Interventional	2007-04-30	Completed
12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder. [NCT00611026]	Phase 3	2,417 participants (Actual)	Interventional	2008-02-29	Completed
Efficacy Study of Tamsulosin and Tolterodine Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Lower Urinary Tract Symptoms [NCT00913315]		30 participants (Anticipated)	Interventional	2009-08-31	Not yet recruiting
Is There A Synergic Effect Of Topical Oestrogens When Associated To Antimuscarinics In The Treatment Of Symptomatic Detrusor Overactivity [NCT00648310]	Phase 2/Phase 3	0 participants	Interventional	2004-01-31	Completed
Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder [NCT00966004]	Phase 3	1,139 participants (Actual)	Interventional	2009-07-31	Completed
A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder [NCT00688688]	Phase 3	2,792 participants (Actual)	Interventional	2008-04-25	Completed
A Randomized, Double-blind, Placebo and Active-controlled Efficacy and Safety Study of SSR240600C in Patients With Overactive Bladder (OAB) or Urge Urinary Incontinence (UUI) [NCT00174798]	Phase 2	118 participants (Actual)	Interventional	2005-05-31	Completed
"Comparison of the Efficacy and Safety of Combination Treatment With Doxazosin Plus TolterodineSR 2 mg vs Doxazosin Plus TolterodineSR 4 mg in Men With an OAB/BPO: Randomized Controlled Study" [NCT00922506]	Phase 4	83 participants (Actual)	Interventional	2009-05-31	Completed
A Randomized, Double Blind, Placebo Controlled, Phase III Study of KUC-7483 in Patients With Overactive Bladder [NCT01004315]	Phase 3	750 participants (Anticipated)	Interventional		Completed
Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder [NCT01043666]	Phase 3	1,126 participants (Actual)	Interventional	2009-12-31	Completed
A 3-Way Cross-Over, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Pharmacologic Effects of a 7-Day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d on Cardiovascular Parameters in Healthy Subjects 50 Years of [NCT00413790]	Phase 4	162 participants (Actual)	Interventional	2006-11-30	Completed
Post-Marketing Study of Mirabegron - A Pharmacokinetic Study to Assess Drug-Drug Interaction Between Mirabegron and Tolterodine - [NCT01964183]	Phase 4	24 participants (Actual)	Interventional	2013-06-30	Completed
Cognitive, Urinary, and Functional Trajectories of Older Women Using Pharmacologic Treatment Strategies for Urgency Incontinence [NCT05362292]	Phase 4	270 participants (Anticipated)	Interventional	2022-10-04	Recruiting
A Randomized, Double-blind, Parallel Group, Proof of Concept Study of YM178 in Comparison With Placebo and Tolterodine in Patients With Symptomatic Overactive Bladder [NCT01604928]	Phase 2	260 participants (Actual)	Interventional	2004-04-30	Completed
Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder. A Randomized Placebo-controlled Crossover Study [NCT02877901]	Phase 2/Phase 3	120 participants (Actual)	Interventional	2016-05-31	Completed
Exploratory, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Center, Web-Based Phase IV Pilot Methodology Trial To Evaluate The Efficacy And Safety Of Tolterodine ER In Subjects With Overactive Bladder [NCT01302938]	Phase 4	18 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Stop date for randomization: 31/5/2012. Recruitment terminated due to lack of recruitment. No new safety issues were identified.)
A Comparison Study on Efficacies of Electrical Pudendal Nerve Stimulation and Tolterodine Tartrate for Urgency-Frequency Syndrome in Women [NCT02723279]		120 participants (Actual)	Interventional	2016-04-30	Completed
Combined Behavioral and Drug Treatment of Overactive Bladder in Men [NCT01175382]	Phase 2/Phase 3	204 participants (Actual)	Interventional	2010-07-31	Completed
A Randomized, Double-Blind, Paralleled, Active Controlled, Multi-Center Study of the Efficacy and Safety of 5mg Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder [NCT00368706]	Phase 3	246 participants (Actual)	Interventional	2006-09-30	Completed
The Applicability of the OAB Assessment Tool for Evaluation of Treatment Efficacy of Overactive Bladder. [NCT00313924]	Phase 4	100 participants	Interventional	2006-02-28	Recruiting
Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects [NCT00332137]	Phase 2	36 participants	Interventional	2005-09-30	Completed
A Multi-centre, Randomised, Placebo Controlled, Double Blind, Parallel Group Study in Female Patients to Evaluate Whether Tolterodine ER Can Reverse the Increased Bladder Wall Thickness in Patients With Overactive Bladder. [NCT00137397]	Phase 4	80 participants	Interventional	2004-11-30	Completed
A Multicenter, Randomized, Double-Blind, Parallel Group, Phase II, Forced Dose Titration Study to Investigate the Efficacy and Safety of 400mg and 600mg ELB245 Given Once Daily for 12 Weeks (8 + 4 Weeks) Versus Placebo and Versus 4mg Tolterodine Given Onc [NCT00439192]	Phase 2	275 participants (Anticipated)	Interventional	2007-02-28	Terminated(stopped due to side effect profile did not match expectations)
A Multi-Center, Double-Phase, Randomized, Double-Blind, Placebo Controlled (12-Week Double-Blind Followed by 12-Week Open-Label) Study Evaluating the Effect of Tolterodine ER on Urgency Urinary Incontinence (UUI), Urgency, Frequency, Sexual Quality of Lif [NCT00143481]	Phase 4	400 participants	Interventional	2005-03-31	Completed
A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Wit [NCT00147654]	Phase 4	830 participants	Interventional	2004-11-30	Completed
A Phase III Randomized, Double-Blind, Double Dummy, Multi-Center Study To Compare The Efficacy, Safety And Tolerability Of Tolterodine Extended Release Capsule With Tolterodine Immediate Release Tablet In Subjects With Symptoms Of Overactive Bladder [NCT00139724]	Phase 3	260 participants (Actual)	Interventional	2005-05-31	Completed
A Randomized, Double-blind, Placebo-controlled, Study of Safety and Efficacy of Dutasteride in Combination With Tolterodine ER or Placebo in Men With Lower Urinary Tract Symptoms (LUTS) Including Urgency and Frequency [NCT00939120]	Phase 4	46 participants (Actual)	Interventional	2009-07-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Three Arm Study To Evaluate The Effects Of Tolterodine ER 4 mg Vs. Placebo Vs. Oxybutynin ER On Memory And Other Cognitive Abilities In Elderly Subjects [NCT00411437]	Phase 4	220 participants	Interventional	2006-12-31	Completed
Evaluation of Sympathetic Skin Responses and Heart Rate Variability as Objective Measures of Bladder Sensation - a Double Blind Third Party Open Placebo Controlled Randomised Study Using a Single Dose of Tolterodine in Patients With Idiopathic Overactive [NCT00481728]	Phase 1	28 participants (Anticipated)	Interventional	2007-06-30	Completed
Is the a Difference Between Rehabilitation Treatment, Pelvic Floor Muscle Training, Bladder Training and Anticholinergic Drug Treatment in UUI in the Long Term: A Study of Impairment, Quality of Life, and Cost Effectiveness [NCT00498888]		164 participants (Actual)	Interventional	2007-06-30	Completed
Randomized Pilot Study on the Treatment of Mixed Urinary Incontinence: Pharmacological Treatment (Tolterodine SR) vs Surgery With Tension Free Vaginal Tape [NCT00523068]	Phase 4	40 participants (Anticipated)	Interventional	2007-09-30	Not yet recruiting
Phase III Study of Propiverine Hydrochloride Extended-Release Capsule in the Treatment of Overactive Bladder (OAB) in Chinese Population With Urgent Micturition, Frequent Micturition and/or Urge Urinary Incontinence [NCT01512004]	Phase 3	324 participants (Actual)	Interventional	2010-01-31	Completed
The Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogren's Syndrome Patient [NCT04909255]	Phase 4	50 participants (Anticipated)	Interventional	2021-03-23	Recruiting
A Single-Dose Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules [NCT01521767]	Phase 1	16 participants (Actual)	Interventional	2011-10-31	Completed
A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC). [NCT00143377]	Phase 4	600 participants	Interventional	2004-09-30	Completed
Overactive Bladder Innovative Therapy Trial [NCT00448175]	Phase 4	100 participants (Actual)	Interventional	2006-06-30	Completed
A Randomized, Placebo Controlled, Crossover Study to Evaluate the Effects of Tolterodine Tartrate on Urodynamic Parameters in Patients With Overactive Bladder [NCT00768521]	Phase 1	20 participants (Actual)	Interventional	2008-09-03	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Standardization of Fluid Intake on the Variability of Measured Voiding Parameters in Female Patients With Idiopathic Overactive Bladder [NCT00553657]	Phase 1	55 participants (Actual)	Interventional	2007-08-31	Completed
A Multicenter, Multiphase, Single Arm, Open Label Study To Evaluate The Effects Of Tolterodine ER In Conjunction With Behavioral Intervention On Subject Satisfaction And Over- Active Bladder Symptoms (Urgency Urinary Incontinence (UUI), Urgency, Frequency [NCT00230789]	Phase 4	417 participants	Interventional	2005-10-31	Completed
"A Randomized, Double Blind, Placebo Controlled Detrol LA Add-On To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency With/Without Urgency Incontinence After Previous Monotherapy With Alpha Blocker." [NCT00282932]	Phase 4	600 participants	Interventional	2006-01-31	Completed
Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome [NCT01503580]		155 participants (Actual)	Interventional	2008-08-31	Completed
Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome - A Prospective Randomized Controlled Comparative Study With Mono-antimuscarinic Therapy [NCT01824420]	Phase 4	129 participants (Actual)	Interventional	2013-03-31	Completed
Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms [NCT01741454]	Phase 4	181 participants (Actual)	Interventional	2012-11-30	Completed
Phase One of Study on Urinary Stent Complications and Treatment [NCT01530243]	Phase 2/Phase 3	104 participants (Actual)	Interventional	2012-01-31	Completed
A Parallel, Double-blind Comparison of Tolterodine vs. Placebo Treatments for Nocturia in Postmenopausal Women. [NCT00323635]	Phase 4	19 participants (Actual)	Interventional	2006-04-30	Terminated(stopped due to New department chairman instructed PI to discontinue study.)
[NCT02436889]	Phase 4	23 participants (Actual)	Interventional	2016-02-29	Completed
Multicenter, Randomized, Double-blind, Parallel, Active Control, Phase III Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With Overactive Bladder Including an Open-label, Extension Study [NCT02485067]	Phase 3	384 participants (Actual)	Interventional	2015-01-31	Completed
Postmarketing Observational Study of Tolterodine Treatment on Overactive Bladder in Real Life Setting [NCT01488578]		11,157 participants (Actual)	Observational	2006-12-31	Completed
Antimuscarinics as the First-line Treatment for Male With International Prostate Symptom Score (IPSS) Voiding-to-storage Subscore Rati (IPSS-V/S)≤1-- A Prospective Randomized Study Comparing With α-blockers [NCT01661621]	Phase 4	395 participants (Actual)	Interventional	2012-08-31	Completed
Protocol for Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence An RCT: Hypnotherapy Or Pharmacotherapy [NCT01829425]		165 participants (Actual)	Interventional	2013-04-22	Completed
A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women [NCT01729819]	Phase 2	106 participants (Actual)	Interventional	2013-01-31	Completed
A Placebo and Active-Comparator Controlled Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of MK-4618 in Patients With Overactive Bladder [NCT01500382]	Phase 1	4 participants (Actual)	Interventional	2012-02-27	Terminated(stopped due to This study was terminated early due to insufficient recruitment.)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB) [NCT02138747]	Phase 4	376 participants (Actual)	Interventional	2014-07-24	Completed
Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in Patients With Overactive Bladder Treated With Mirabegron [NCT02294396]	Phase 4	649 participants (Actual)	Interventional	2014-10-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00090584 (9) [back to overview]	Symptom Improvement
NCT00090584 (9) [back to overview]	Satisfaction
NCT00090584 (9) [back to overview]	Satisfaction
NCT00090584 (9) [back to overview]	Change in Incontinence Episodes
NCT00090584 (9) [back to overview]	Proportion of Women Who Meet Definition of Success
NCT00090584 (9) [back to overview]	Symptom Distress
NCT00090584 (9) [back to overview]	Change in Voids Per Day
NCT00090584 (9) [back to overview]	Symptom Improvement
NCT00090584 (9) [back to overview]	Symptom Bother
NCT00444925 (19) [back to overview]	Percent Change From Baseline of UUI Episodes Per 24 Hours.
NCT00444925 (19) [back to overview]	Percent Change From Baseline of Micturitions Per 24 Hours.
NCT00444925 (19) [back to overview]	Percent Change From Baseline of Nocturnal Micturitions Per 24 Hours.
NCT00444925 (19) [back to overview]	Percent Change From Baseline of Severe Urgency Episodes Per 24 Hours.
NCT00444925 (19) [back to overview]	Percent Change From Baseline of Urgency Episodes Per 24 Hours.
NCT00444925 (19) [back to overview]	Change From Baseline in Mean Number of UUI Episodes Per 24 Hours at Week 1 and Week 4.
NCT00444925 (19) [back to overview]	Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment).
NCT00444925 (19) [back to overview]	Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score at Week 12 (End of Treatment).
NCT00444925 (19) [back to overview]	Change From Baseline in Frequency-Urgency Sum (Formerly Known as Urinary Sensations Scale Sum in Protocol) Per 24 Hours.
NCT00444925 (19) [back to overview]	Change From Baseline in Mean Number of Micturitions Per 24 Hours.
NCT00444925 (19) [back to overview]	Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours.
NCT00444925 (19) [back to overview]	Change From Baseline in Mean Number of Severe Urgency Episodes Per 24 Hours.
NCT00444925 (19) [back to overview]	Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours.
NCT00444925 (19) [back to overview]	Change From Baseline in Mean USS Rating Per Micturition Per 24 Hours.
NCT00444925 (19) [back to overview]	Change From Baseline in Mean Voided Volume Per Micturition.
NCT00444925 (19) [back to overview]	Change From Baseline in OAB-q: Health Related Quality of Life (HRQL) at Week 12 (End of Treatment).
NCT00444925 (19) [back to overview]	Change From Baseline in Patient Perception of Bladder Condition (PPBC).
NCT00444925 (19) [back to overview]	Change From Baseline in Urgency Perception Scale (UPS). UPS Equals Patient Perception of Urgency Scale (PPUS) in Protocol.
NCT00444925 (19) [back to overview]	Diary Dry Rates
NCT00448175 (1) [back to overview]	Frequency of Voids at 12 Weeks
NCT00465894 (13) [back to overview]	Subjective Patient Change in Irritative Symptoms as Indicated by the Patient Global Impression of Improvement (PGI-I)
NCT00465894 (13) [back to overview]	Subjective Patient Change in Irritative Urinary Symptoms As Measured By the 3-Day Voiding Diary
NCT00465894 (13) [back to overview]	Evaluate Subjective Patient Change in Irritative Urinary Symptoms as Measured by the Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
NCT00465894 (13) [back to overview]	Subjective Patient Change in Irritative Urinary Symptoms as Indicated by the Patient Global Impression of Improvement (PGI-I)
NCT00465894 (13) [back to overview]	Subjective Patient Change in Irritative Urinary Symptoms as Indicated by the Patient Satisfaction Questionnaire (PSQ)
NCT00465894 (13) [back to overview]	Subjective Patient Change in Irritative Urinary Symptoms as Indicated by the Patient Satisfaction Questionnaire (PSQ)
NCT00465894 (13) [back to overview]	Evaluate Subjective Patient Change in Irritative Urinary Symptoms
NCT00465894 (13) [back to overview]	Subjective Patient Change in Irritative Urinary Symptoms
NCT00465894 (13) [back to overview]	Evaluate Subjective Patient Change in Irritative Urinary Symptoms as Measured by the Health Related Quality of Life (HRQL)
NCT00465894 (13) [back to overview]	Subjective Patient Change in Irritative Urinary Symptoms
NCT00465894 (13) [back to overview]	Subjective Patient Change in Irritative Urinary Symptoms
NCT00465894 (13) [back to overview]	Subjective Patient Change in Irritative Urinary Symptoms
NCT00465894 (13) [back to overview]	Subjective Patient Change in Irritative Urinary Symptoms
NCT00611026 (20) [back to overview]	Percent Change From Baseline of UUI Episodes Per 24 Hours
NCT00611026 (20) [back to overview]	Post-hoc Adverse Events (AEs)
NCT00611026 (20) [back to overview]	Percent Change From Baseline of Severe Urgency Episodes Per 24 Hours
NCT00611026 (20) [back to overview]	Change From Baseline in Mean Number of Urgency Urinary Episodes Per 24 Hours (Urinary Sensation Scale ≥3 in the Diary)
NCT00611026 (20) [back to overview]	Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12
NCT00611026 (20) [back to overview]	Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score at Week 12
NCT00611026 (20) [back to overview]	Change From Baseline in Frequency-Urgency Sum (FUS) Per 24 Hours (Synonymous With USS Sum in the Study Protocol)
NCT00611026 (20) [back to overview]	Change From Baseline in Mean Number of Micturitions Per 24 Hours
NCT00611026 (20) [back to overview]	Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours
NCT00611026 (20) [back to overview]	Change From Baseline in Mean Number of Severe Urgency Episodes Per 24 Hours
NCT00611026 (20) [back to overview]	Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 1 and Week 4
NCT00611026 (20) [back to overview]	Change From Baseline in Mean Urinary Sensation Scale (USS) Rating Per Micturition Per 24 Hours.
NCT00611026 (20) [back to overview]	Change From Baseline in Mean Voided Volume Per Micturition
NCT00611026 (20) [back to overview]	Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Health Related Quality of Life (HRQL) at Week 12
NCT00611026 (20) [back to overview]	Change From Baseline in Patient Perception of Bladder Condition (PPBC)
NCT00611026 (20) [back to overview]	Change From Baseline in Urgency Perception Scale (UPS). UPS Formerly Known as Patient Perception of Urgency Scale (PPUS) in the Protocol.
NCT00611026 (20) [back to overview]	Diary Dry Rate: Percentage of Participants With no Urgency Urinary Incontinence (UUI) in the 3-day Bladder Diary
NCT00611026 (20) [back to overview]	Percent Change From Baseline in Mean Number of Urgency Urinary Episodes Per 24 Hours (Urinary Sensation Scale ≥3 in the Diary)
NCT00611026 (20) [back to overview]	Percent Change From Baseline of Micturitions Per 24 Hours
NCT00611026 (20) [back to overview]	Percent Change From Baseline of Nocturnal Micturitions Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Number of Incontinence Episodes Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Health-related Quality of Life (HRQL) Total Score
NCT00688688 (28) [back to overview]	Change From Baseline to Month 12 and Final Visit in Treatment Satisfaction-visual Analog Scale (TS-VAS)
NCT00688688 (28) [back to overview]	Change From Baseline to Month 12 and Final Visit in Patient Perception of Bladder Condition (PPBC)
NCT00688688 (28) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score
NCT00688688 (28) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Self-Care Score
NCT00688688 (28) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score
NCT00688688 (28) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score
NCT00688688 (28) [back to overview]	Percentage of Participants With Improvement in Patient Perception of Bladder Condition (PPBC)
NCT00688688 (28) [back to overview]	Percentage of Participants With ≥ 50% Reduction in Incontinence Episodes at Months 1, 3, 6, 9 and 12 and the Final Visit
NCT00688688 (28) [back to overview]	Number of Participants With and Severity of Treatment-emergent Adverse Events (TEAEs)
NCT00688688 (28) [back to overview]	Change From Baseline to Months 3, 6, 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed
NCT00688688 (28) [back to overview]	Change From Baseline to Months 3, 6, 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Months 3, 6, 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working
NCT00688688 (28) [back to overview]	Percentage of Participants With Zero Incontinence Episodes at Months 1, 3, 6, 9 and 12 and the Final Visit
NCT00688688 (28) [back to overview]	Change From Baseline to Months 3, 6, 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment
NCT00688688 (28) [back to overview]	Change From Baseline to Months 3, 6, 12 and Final Visit in Number of Non-study Related Visits to Physician
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in the Mean Number of Pads Used Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in the European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Symptom Bother Score
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Volume Voided Per Micturition
NCT00688688 (28) [back to overview]	Safety as Assessed by Adverse Events (AEs), Vital Signs, Laboratory Tests, Physical Examination and Electrocardiogram
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Number of Micturitions Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Level of Urgency
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Number of Nocturia Episodes Per 24 Hours
NCT00688688 (28) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and Final Visit in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours
NCT00689104 (31) [back to overview]	Percentage of Participants With Zero Incontinence Episodes at Week 4, Week 8, Week 12 and the Final Visit
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score
NCT00689104 (31) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to End of Treatment (Final Visit) in Mean Number of Micturitions Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in Mean Volume Voided Per Micturition
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4 in Mean Number of Incontinence Episodes Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4 in Mean Number of Micturitions Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Self-care Score
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score
NCT00689104 (31) [back to overview]	Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D)Anxiety/Depression Score
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Patient Perception of Bladder Condition (PPBC)
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Treatment Satisfaction on Visual Analog Scale (TS-VAS)
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment
NCT00689104 (31) [back to overview]	Change From Baseline to Week 12 and Final Visit in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8 and Week 12 in Mean Volume Voided Per Micturition
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Health-related Quality of Life (HRQL) Total Score
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Level of Urgency
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Nocturia Episodes Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Pads Used Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Urgency Episodes (Grades 3 or 4) Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Number of Non-study Related Visits to Physician
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in Symptom Bother Score
NCT00689104 (31) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and Final Visit in the European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)
NCT00689104 (31) [back to overview]	Change From Baseline to Week 8 and Week 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT00689104 (31) [back to overview]	Change From Baseline to Week 8 and Week 12 in Mean Number of Micturitions Per 24 Hours
NCT00689104 (31) [back to overview]	Percentage of Participants With ≥ 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and the Final Visit
NCT00689104 (31) [back to overview]	Percentage of Participants With Improvement in Patient Perception of Bladder Condition (PPBC) at Week 12 and Final Visit
NCT00768521 (2) [back to overview]	Change From Baseline in Maximum Cystometric Capacity at 4 Hours Post Dose 1 on Tolterodine 4 mg and Placebo
NCT00768521 (2) [back to overview]	Change From Baseline in Maximum Cystometric Capacity at 4 Hours Post Dose 7 on Tolterodine 4 mg and Placebo
NCT00795509 (2) [back to overview]	Adverse Drug Reaction Not Expected From the Japanese Package Insert. Number of Unlisted Treatment Related Adverse Events (TRAEs).
NCT00795509 (2) [back to overview]	Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs).
NCT00939120 (9) [back to overview]	Maximum Urine Flow Rate (Qmax).
NCT00939120 (9) [back to overview]	Patient Perception of Bladder Condition (PPBC)
NCT00939120 (9) [back to overview]	Post-void Residual (PVR) Volume
NCT00939120 (9) [back to overview]	Overactive Bladder Questionnaire (OABq)
NCT00939120 (9) [back to overview]	Urine Voided Volume (Voiding)
NCT00939120 (9) [back to overview]	International Prostate Symptoms Score, Voiding Subscore
NCT00939120 (9) [back to overview]	Acute Urinary Retention (AUR)
NCT00939120 (9) [back to overview]	International Prostate Symptoms Score (IPSS), Storage Subscore
NCT00939120 (9) [back to overview]	International Prostate Symptoms Score (IPSS), Total
NCT01175382 (18) [back to overview]	Change in Frequency of Urination From 6 Weeks to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Frequency of Urination After 6-week Intervention (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Frequency of Urination From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Nocturia From Baseline to 6 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in International Prostate Symptom Score (I-PSS) From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in International Prostate Symptom Score (I-PSS) From Baseline to 6 Weeks. (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in International Prostate Symptom Score (IPSS) From 6 to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Nocturia From 6 Weeks to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Nocturia Measured From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Overactive Bladder Questionnaire (OAB-q) From 6 to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Overactive Bladder Questionnaire (OAB-q) From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Overactive Bladder Questionnaire (OAB-q) From Baseline to 6 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urgency From Baseline to 6 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urgency Score From 6 Weeks to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urinary Incontinence Episodes From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urinary Incontinence From 6 Weeks to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urinary Incontinence From Baseline to 6 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urgency Score From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01302938 (20) [back to overview]	Change From Baseline in Mean Voided Volume Per Micturition at Week 1, 4 and 12
NCT01302938 (20) [back to overview]	Participant Perception Regarding Recommending a Friend to Enter Similar Study
NCT01302938 (20) [back to overview]	Participant Perception Regarding Received Treatment in the Study
NCT01302938 (20) [back to overview]	Participant Perception Regarding Cell Phone Diary
NCT01302938 (20) [back to overview]	Number of Participants Who Discontinued the Study Due to Adverse Events
NCT01302938 (20) [back to overview]	Number of Participants With Laboratory Abnormalities
NCT01302938 (20) [back to overview]	Change From Baseline in Health Related Quality of Life (HRQL) Domains and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12
NCT01302938 (20) [back to overview]	Change From Baseline in Health Related Quality of Life (HRQL) Social Domain Score at Week 12
NCT01302938 (20) [back to overview]	Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 1, 4 and 12
NCT01302938 (20) [back to overview]	Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 1 and 4
NCT01302938 (20) [back to overview]	Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12
NCT01302938 (20) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
NCT01302938 (20) [back to overview]	Number of Participants With Response Regarding Source of First Information About Study
NCT01302938 (20) [back to overview]	Participant Perception Regarding Satisfaction Related to Study
NCT01302938 (20) [back to overview]	Number of Participants With Reason for Participation in the Study
NCT01302938 (20) [back to overview]	Number of Participants With Change From Baseline in Patient Perception of Urgency Scale (PPUS) at Week 1, 4 and 12
NCT01302938 (20) [back to overview]	Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Week 1, 4 and 12
NCT01302938 (20) [back to overview]	Number of Participants With Adverse Events (AEs) by Relatedness and Severity
NCT01302938 (20) [back to overview]	Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 12
NCT01302938 (20) [back to overview]	Change From Baseline in Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 1, 4 and 12
NCT01314872 (12) [back to overview]	Extension Study: Number of Participants Who Experienced an Adverse Event (AE)
NCT01314872 (12) [back to overview]	Extension Study: Change From Baseline in Average Daily Number of Urge Incontinence Episodes at Week 52
NCT01314872 (12) [back to overview]	Extension Study: Change From Baseline in Average Daily Number of Total Incontinence Episodes at Week 52
NCT01314872 (12) [back to overview]	Extension Study: Change From Baseline in Average Daily Micturitions at Week 52
NCT01314872 (12) [back to overview]	Extension Study: Change From Baseline in Average Daily Number of Strong Urge Episodes at Week 52
NCT01314872 (12) [back to overview]	Base Study/Part 1: Change From Baseline in Average Daily Number of Strong Urge Episodes at Week 8
NCT01314872 (12) [back to overview]	Base Study/Part 1 + Part 2: Number of Participants Who Experienced an Adverse Event (AE)
NCT01314872 (12) [back to overview]	Base Study/Part 1 + Part 2: Number of Participants Who Had Study Medication Withdrawn Due to an AE
NCT01314872 (12) [back to overview]	Base Study/Part 1: Change From Baseline in Average Daily Micturitions at Week 8
NCT01314872 (12) [back to overview]	Base Study/Part 1: Change From Baseline in Average Daily Number of Total Incontinence Episodes at Week 8
NCT01314872 (12) [back to overview]	Base Study/Part 1: Change From Baseline in Number of Urge Incontinence Episodes at Week 8
NCT01314872 (12) [back to overview]	Extension Study: Number of Participants Who Had Study Medication Withdrawn Due to an AE
NCT01488578 (16) [back to overview]	Risk Factors for the Proportion of Responders of Tolterodine-Severity of Overactive Bladder
NCT01488578 (16) [back to overview]	Risk Factors for the Proportion of Responders of Tolterodine-Previous Treatment
NCT01488578 (16) [back to overview]	Risk Factors for the Proportion of Responders of Tolterodine-Number of Urinations Per Day (During Sleep)
NCT01488578 (16) [back to overview]	Risk Factors for the Proportion of Responders of Tolterodine-Non-drug Therapies
NCT01488578 (16) [back to overview]	Risk Factors for the Proportion of Responders of Tolterodine-Gender
NCT01488578 (16) [back to overview]	Risk Factors for the Proportion of Responders of Tolterodine-Concomitant Drugs
NCT01488578 (16) [back to overview]	Risk Factors for the Proportion of Responders of Tolterodine-Complications
NCT01488578 (16) [back to overview]	Risk Factors for the Proportion of Responders of Tolterodine-Age
NCT01488578 (16) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Tolterodine - Comorbidity of Prostatic Hypertrophy
NCT01488578 (16) [back to overview]	Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs).
NCT01488578 (16) [back to overview]	Risk Factors for the Proportion of Responders of Tolterodine-Number of Urinary Incontinence Episodes Per Day
NCT01488578 (16) [back to overview]	Number of Unlisted Treatment Related Adverse Events (TRAEs)Reported in at Least 5 Participants
NCT01488578 (16) [back to overview]	Number of Participants With an Investigator's Assessment of Clinical Outcome at End of the Study.
NCT01488578 (16) [back to overview]	Confirmation of Frequent Treatment Related Adverse Events (TRAEs) at the End of Observation Period.
NCT01488578 (16) [back to overview]	"Number of Participants Which Was Evaluated as Degree of Satisfaction."
NCT01488578 (16) [back to overview]	Risk Factors for the Proportion of Responders of Tolterodine-Urinary Urgency
NCT01500382 (2) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT01500382 (2) [back to overview]	Number of Participants Who Discontinued Use of Study Drug Due to an AE
NCT01530243 (3) [back to overview]	Lower Urinary Tract Symptoms (LUTS)
NCT01530243 (3) [back to overview]	Pain
NCT01530243 (3) [back to overview]	Quality of Life
NCT01661621 (8) [back to overview]	The Global Response Assessment (GRA) After the Treatment Day
NCT01661621 (8) [back to overview]	The International Prostate Symptom Score (IPSS) Quality of Life (QoL) Score After the Treatment Day
NCT01661621 (8) [back to overview]	The International Prostate Symptom Score (IPSS) Questionnaires After the Treatment Day
NCT01661621 (8) [back to overview]	The IPSS Subscore (IPSS Storage) Questionnaires After the Treatment Day
NCT01661621 (8) [back to overview]	The IPSS Subscore (IPSS Voiding) Questionnaires After the Treatment Day
NCT01661621 (8) [back to overview]	The Voided Volume After the Treatment Day
NCT01661621 (8) [back to overview]	The Maximum Flow Rate (Qmax) After the Treatment Day
NCT01661621 (8) [back to overview]	The Postvoid Residual Volume (PVR) After the Treatment Day
NCT01729819 (6) [back to overview]	Change in Mean Nocturnal Urine Volume From Baseline
NCT01729819 (6) [back to overview]	Change in Mean Number of Nocturnal Voids From Baseline
NCT01729819 (6) [back to overview]	Change in Mean Time to First Nocturnal Void From Baseline
NCT01729819 (6) [back to overview]	Responder Status
NCT01729819 (6) [back to overview]	Change in the Impact on Sleep as Measured by the Sleep Rating Scales From Baseline
NCT01729819 (6) [back to overview]	Onset of Effect as Seen in Change in Mean Number of Nocturnal Voids From Baseline for Each Visit During Three Months of Treatment
NCT01741454 (4) [back to overview]	Ureteral Stent Symptom Questionnaire Score
NCT01741454 (4) [back to overview]	Ureteral Stent Symptom Questionnaire Score 5-7 Days Post-stent Insertion
NCT01741454 (4) [back to overview]	Ureteral Stent Symptom Questionnaire Score Up to 24 Hours After Stent Removal
NCT01741454 (4) [back to overview]	Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion
NCT01829425 (12) [back to overview]	Percent Change in Urgency Urinary Incontinence Episodes
NCT01829425 (12) [back to overview]	Percent Change in Urgency Urinary Incontinence Episodes
NCT01829425 (12) [back to overview]	Voids on Bladder Diary
NCT01829425 (12) [back to overview]	Voids on Bladder Diary
NCT01829425 (12) [back to overview]	Overactive Bladder Questionnaire Short Form Quality of Life
NCT01829425 (12) [back to overview]	Overactive Bladder Questionnaire Short Form Quality of Life
NCT01829425 (12) [back to overview]	Overactive Bladder Questionnaire Short Form Quality of Life
NCT01829425 (12) [back to overview]	Overactive Bladder Questionnaire Short Form Symptom Bother
NCT01829425 (12) [back to overview]	Voids on Bladder Diary
NCT01829425 (12) [back to overview]	Overactive Bladder Questionnaire Short Form Symptom Bother
NCT01829425 (12) [back to overview]	Percent Change in Urgency Urinary Incontinence Episodes
NCT01829425 (12) [back to overview]	Overactive Bladder Questionnaire Short Form Symptom Bother
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Overall Assessment of Improvement in Day-to-Day Life Due to OAB Medication
NCT02138747 (13) [back to overview]	Change From Baseline to End of Treatment (EOT) in Mean Number of Incontinence Episodes Per 24 Hours
NCT02138747 (13) [back to overview]	Change From Baseline to End of Treatment (EOT) in Number of Micturitions Per 24 Hours
NCT02138747 (13) [back to overview]	Participants Tolerability Assessed by the Medication Tolerability Scale of the Overactive Bladder-Satisfaction (OAB-S) Questionnaire at the End of Treatment (EOT)
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Impact on Daily Living With OAB.
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: OAB Control
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Overall Assessment of Interruption of Day-to-Day Life Due to OAB
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Overall Assessment of Participant's Fulfillment of OAB Medication Expectations
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Overall Assessment of Willingness to Continue OAB Medication
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Overall Satisfaction With OAB Medication
NCT02138747 (13) [back to overview]	Scale of the OAB-S Questionnaire at the End of Treatment Period: Satisfaction With OAB Control
NCT02138747 (13) [back to overview]	Number of Participants With Adverse Events
NCT02138747 (13) [back to overview]	Participants Preference Based on a 5-Point Scale at the End of Period 2 in Participants Who Completed at Least 14 Days of Study Drug in Both Study Treatment Periods.
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Volume Voided Per Micturition
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Urgency Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Urge Incontinence Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Nocturia Episodes Per Night
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Micturitions Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Incontinence Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in Overactive Bladder Symptom Score (OABSS) Total Score
NCT02294396 (16) [back to overview]	Change From Baseline in Postvoid Residual (PVR) Volume
NCT02294396 (16) [back to overview]	Change From Baseline in Overactive Bladder Questionnaire Short Form (OAB-q SF) Symptom Severity Score
NCT02294396 (16) [back to overview]	Change From Baseline in OAB-q SF Total HRQL Score
NCT02294396 (16) [back to overview]	Number of Participants Who Achieved Normalization of the Mean Number of Nocturia Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Number of Participants Who Achieved Normalization for OABSS Total Score
NCT02294396 (16) [back to overview]	Number for Participants Who Achieved Normalization of the Mean Number of Urgency Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Number for Participants Who Achieved Normalization of the Mean Number of Micturitions Per 24 Hours
NCT02294396 (16) [back to overview]	Number for Participants Who Achieved Normalization of the Mean Number of Incontinence Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02436889 (5) [back to overview]	Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks
NCT02436889 (5) [back to overview]	Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks
NCT02436889 (5) [back to overview]	Change From Baseline in Urge Incontinence Episodes Per Day on a Voiding Diary at 8 Weeks.
NCT02436889 (5) [back to overview]	Change From Baseline in Total Urinary Incontinence Frequency Measured by a Voiding Diary at 8 Weeks
NCT02436889 (5) [back to overview]	Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks
NCT03492281 (15) [back to overview]	Percentage of OAB Wet Participants With at Least a 50% Reduction From Baseline in Total Incontinence Episodes Per 24 Hours at Week 12
NCT03492281 (15) [back to overview]	Percentage of OAB Wet Participants With a 100% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12
NCT03492281 (15) [back to overview]	Percentage of All OAB Participants With at Least a 50% Reduction From Baseline in Urgency Episodes Per 24 Hours at Week 12
NCT03492281 (15) [back to overview]	Percentage of All OAB Participants With an Average Number of Micturitions < 8 Per 24 Hours at Week 12
NCT03492281 (15) [back to overview]	CFB at Week 12 in the Symptom Bother Score From the OAB-q LF (1-week Recall) in All OAB Participants
NCT03492281 (15) [back to overview]	CFB at Week 12 in the Health-related Quality of Life (HRQL) Total Score From the OAB-q LF (1-week Recall) in All OAB Participants
NCT03492281 (15) [back to overview]	CFB at Week 12 in the Coping Score From the Overactive Bladder Questionnaire Long Form (OAB-q LF, 1-week Recall) in All OAB Participants
NCT03492281 (15) [back to overview]	CFB at Week 12 in the Average Volume Voided Per Micturition in All OAB Participants
NCT03492281 (15) [back to overview]	CFB at Week 12 in the Average Number of Urgency Episodes Over 24 Hours in All OAB Participants
NCT03492281 (15) [back to overview]	CFB at Week 12 in the Average Number of Urge Urinary Incontinence (UUI) Episodes Per 24 Hours in OAB Wet Participants
NCT03492281 (15) [back to overview]	CFB at Week 12 in the Average Number of Total Incontinence Episodes Over 24 Hours in OAB Wet Participants
NCT03492281 (15) [back to overview]	CFB at Week 12 in Overall Control Over Bladder Symptoms Based on Patient Global Impression of Control (PGI-Control) in All OAB Participants
NCT03492281 (15) [back to overview]	CFB at Week 12 in Overall Bladder Symptoms Based on Patient Global Impression of Severity (PGI-Severity) in All OAB Participants
NCT03492281 (15) [back to overview]	Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants
NCT03492281 (15) [back to overview]	Percentage of OAB Wet Participants With at Least a 75% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12
NCT03575702 (15) [back to overview]	Changes in the Volume of Residual Urine
NCT03575702 (15) [back to overview]	Changes in the Overactive Bladder Symptom Score According to Overactive Bladder (OAB) Awareness Tool Questionnaire at 2, 4, 8 and 12 Week
NCT03575702 (15) [back to overview]	Change in the Mean Weekly Number of Incontinence Episodes at Week 12
NCT03575702 (15) [back to overview]	Change in the Mean Number of Incontinence Episodes at Week 2, 4 and 8
NCT03575702 (15) [back to overview]	Change in the Mean Nighttime Number of Incontinence Episodes at Week 12
NCT03575702 (15) [back to overview]	Change in the Mean Daytime Number of Incontinence Episodes at Week 12
NCT03575702 (15) [back to overview]	Number of Patients With Adverse Events (AEs)
NCT03575702 (15) [back to overview]	Number of Patients With Clinically Significant Changes in ECG Parameters
NCT03575702 (15) [back to overview]	Number of Patients With Clinically Significant Vital Signs Changes
NCT03575702 (15) [back to overview]	Number of Patients With Serious Adverse Events (SAEs)
NCT03575702 (15) [back to overview]	Change in the EQ-5D-based Quality of Life at Week 12
NCT03575702 (15) [back to overview]	Change in the Mean Daily Number of Incontinence Episodes at Week 12
NCT03575702 (15) [back to overview]	Change in the Mean Daily Number of Urination Episodes at Week 12
NCT03575702 (15) [back to overview]	Change in the Mean Daily Number of Urination Episodes at Week 2, 4 and 8 Visit as Compared to the Treatment Initiation Visit
NCT03575702 (15) [back to overview]	Number of Patients With Clinically Significant Changes in Laboratory Parameters
NCT03583372 (5) [back to overview]	CFB at Week 52 in the Average Number of Urge Urinary Incontinence (UUI) Episodes Per 24 Hours in OAB Wet Participants
NCT03583372 (5) [back to overview]	CFB at Week 52 in the Average Number of Urgency Episodes (Need to Urinate Immediately) Over 24 Hours in All OAB Participants
NCT03583372 (5) [back to overview]	Change From Baseline (CFB) at Week 52 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants
NCT03583372 (5) [back to overview]	Number of Participants With the Indicated Type of Treatment-emergent Adverse Event
NCT03583372 (5) [back to overview]	CFB at Week 52 in the Average Number of Total Urinary Incontinence Episodes Over 24 Hours in OAB Wet Participants
NCT04090190 (2) [back to overview]	The Effectiveness of Anticholinergic Treatment in Relation to the Urinary Microbiome. Culture to Standard Culture Media Will Pickup Aerobic Bacteria and Yeasts After DNA Extraction and End Point PCR for 16S rDNA Genes.
NCT04090190 (2) [back to overview]	Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu.

Symptom Improvement

"Number of women who responded much better or better to question: Overall, do you feel that you are much better, better, about the same, worse or much worse?" (NCT00090584)
Timeframe: 8 months

Intervention	participants (Number)
Combination Therapy	80
Drug Therapy Alone	54

Intervention	units on a scale (Mean)
Combination at Baseline	121.4
Combination at 10 Weeks	47.3
Combiniation at 8 Months	61.9
Drug Only at Baseline	118.2
Drug Only at 10 Weeks	58.1
Drug Only at 8 Months	83.3

Intervention	units on a scale (Mean)
Combination at Baseline	59.9
Combination at 10 Weeks	23.1
Combiniation at 8 Months	29.0
Drug Only at Baseline	60.0
Drug Only at 10 Weeks	29.6
Drug Only at 8 Months	39.6

Intervention	percent change (Median)
	Week 1 (n=302, 614, 612)	Week 4 [LOCF] (n=307, 626, 618)	Week 12 [LOCF] (n=307, 626, 619)
Fesoterodine	-53.6	-93.2	-100.0
Placebo	-28.6	-60.0	-82.1
Tolterodine ER	-55.1	-85.7	-100.0

Intervention	percent change (Median)
	Week 1 (n=307, 622, 623)	Week 4 [LOCF] (n=313, 634, 627)	Week 12 [LOCF] (n=313, 634, 628)
Fesoterodine	-7.9	-14.8	-18.9
Placebo	-2.7	-10.3	-12.1
Tolterodine ER	-7.7	-15.0	-16.2

Intervention	percent change (Median)
	Week 1 (n=288, 584, 596)	Week 4 [LOCF] (n=293, 596, 600)	Week 12 [LOCF] (n=293, 596, 601)
Fesoterodine	0.0	-20.0	-28.6
Placebo	-10.0	-22.2	-25.0
Tolterodine ER	-12.5	-25.0	-27.9

Intervention	percent change (Median)
	Week 1 (n=306, 618, 618)	Week 4 [LOCF] (n=311, 630, 624)	Week 12 [LOCF] (n=311, 630, 625)
Fesoterodine	-25.0	-54.5	-71.4
Placebo	-9.4	-25.0	-48.0
Tolterodine ER	-25.0	-45.8	-63.4

Intervention	percent change (Median)
	Week 1 (n=306, 619, 621)	Week 4 [LOCF] (n=311,631, 627)	Week 12 [LOCF] (n=311, 631, 628)
Fesoterodine	-9.7	-26.9	-37.9
Placebo	-5.6	-11.4	-17.6
Tolterodine ER	-12.5	-23.1	-30.8

Intervention	number of micturitions per 24 hours (Least Squares Mean)
	Week 1 (n=307, 622, 623)	Week 4 [LOCF] (n= 313, 634, 627)	Week 12 [LOCF] (n= 313, 634, 628)
Fesoterodine	-1.0	-1.9	-2.2
Placebo	-0.5	-1.2	-1.5
Tolterodine ER	-1.0	-1.8	-2.1

Intervention	urgency episodes per 24 hours (Least Squares Mean)
	Week 1 (n=306, 619, 621)	Week 4 [LOCF] (n=311, 631, 627)	Week 12 [LOCF] (n=311, 631, 628)
Fesoterodine	-1.1	-2.6	-3.5
Placebo	-0.4	-1.2	-2.0
Tolterodine ER	-1.3	-2.4	-3.1

Intervention	voided volume per micturition (Least Squares Mean)
	Week 1 (n=306, 622, 623)	Week 4 [LOCF] (n=313, 633, 625)	Week 12 [LOCF] (n=313, 633, 626)
Fesoterodine	18.7	30.5	32.9
Placebo	11.0	14.0	16.8
Tolterodine ER	19.2	25.7	23.5

Intervention	score on scale (Least Squares Mean)
	HRQL concern domain (n=289, 589, 572)	HRQL coping domain (n=289, 589, 572)	HRQL sleep domain (n=289, 589, 572)	HRQL social interaction domain (n=289, 588, 572)	HRQL scale score total (n=289, 588, 572)
Fesoterodine	22.6	22.6	17.3	11.6	19.3
Placebo	13.4	14.0	12.2	6.8	12.0
Tolterodine ER	19.3	18.5	15.1	9.4	16.3

Intervention	participants (Number)
	Week 1 (n=309, 625, 623), >=2 points improvement	Week 1, 1-point improvement	Week 1, no change	Week 1, deterioration	Week 4 (n=313, 632, 629), >=2 points improvement	Week 4, 1-point improvement	Week 4, no change	Week 4, deterioration	Week 12 (n=313, 632, 630), >=2 points improvement	Week 12, 1-point improvement	Week 12, no change	Week 12, deterioration
Fesoterodine	102	186	286	49	196	224	176	33	254	198	148	30
Placebo	32	94	147	36	57	95	127	34	67	102	111	33
Tolterodine ER	79	181	306	59	169	201	203	59	210	189	171	62

Intervention	participants (Number)
	Week 1 (n=309, 627, 624), improvement	Week 1, no change	Week 1, deterioration	Week 4 (n=313, 633, 629), improvement	Week 4, no change	Week 4, deterioration	Week 12 (n=313, 633, 630), improvement	Week 12, no change	Week 12, deterioration
Fesoterodine	171	413	40	256	348	25	291	314	25
Placebo	68	218	23	98	194	21	112	181	20
Tolterodine ER	162	438	27	238	362	33	254	344	35

Intervention	participants (Number)
	Week 1	Week 4	Week 12
Fesoterodine	159	306	396
Placebo	54	97	138
Tolterodine ER	153	290	358

Intervention	percentage of participants (Number)
Group 1: Extended Release Tolterodine + Intravaginal Estradiol	85
Group 2: Intravaginal Estradiol Cream	85

Intervention	events (Mean)
	Number of voids	Number of voids 12 week follow-up	Number of accidents/leakage	Number of accidents/leakage at 12 weeks
Group 1: Extended Release Tolterodine	30.4	26.3	10.8	7.2
Group 2: Intravaginal Estradiol Cream	26.4	24.6	11.9	7.7

Intervention	units on a scale (Mean)
	Baseline	12 Weeks
Group 1: Extended Release Tolterodine	65.4	46.7
Group 2: Intravaginal Estradiol Cream	61.6	45.4

Intervention	percentage of participants (Number)
Group 1: Extended Release Tolterodine + Intravaginal Estradiol	77
Group 2: Intravaginal Estradiol Cream + Tolterodine	77

Intervention	participants (Number)
	Very Much Better	Much Better	A Little Better	No Change	A Litlle Worse
Group 1: Extended Release Tolterodine	3	8	8	5	1
Group 2: Intravaginal Estradiol Cream	0	7	12	5	0

Intervention	participants (Number)
	Completely Satisfied	Somewhat Satisfied	Not Satisfied
Extended Release Tolterodine LA	5	13	6
Intravaginal Estradiol Cream	3	13	8

Intervention	units on a scale (Mean)
	Baseline	12 weeks
Extended Release Tolterodine	53.1	66.0
Intravaginal Estradiol Cream	60.9	69.8

Intervention	units on a scale (Mean)
Group 1: Extended Release Tolterodine + Intravaginal Estradiol	26.8
Group 2: Intravaginal Estradiol Cream	19.7

Intervention	units on a scale (Mean)
Group 1: Extended Release Tolterodine + Intravaginal Estradiol	-23.4
Intravaginal Estradiol Cream + Tolterodine	-31.3

tolterodine tartrate

Description

Cross-References

Synonyms (5)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Research

Studies (681)

Study Types

Clinical Trials (89)

Trial Overview

Trial Outcomes

Symptom Improvement

Satisfaction

Satisfaction

Change in Incontinence Episodes

Proportion of Women Who Meet Definition of Success

Symptom Distress

Change in Voids Per Day

Symptom Improvement

Symptom Bother

Percent Change From Baseline of UUI Episodes Per 24 Hours.

Percent Change From Baseline of Micturitions Per 24 Hours.

Percent Change From Baseline of Nocturnal Micturitions Per 24 Hours.

Percent Change From Baseline of Severe Urgency Episodes Per 24 Hours.

Percent Change From Baseline of Urgency Episodes Per 24 Hours.

Change From Baseline in Mean Number of UUI Episodes Per 24 Hours at Week 1 and Week 4.

Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment).

Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score at Week 12 (End of Treatment).

Change From Baseline in Frequency-Urgency Sum (Formerly Known as Urinary Sensations Scale Sum in Protocol) Per 24 Hours.

Change From Baseline in Mean Number of Micturitions Per 24 Hours.

Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours.

Change From Baseline in Mean Number of Severe Urgency Episodes Per 24 Hours.

Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours.

Change From Baseline in Mean USS Rating Per Micturition Per 24 Hours.

Change From Baseline in Mean Voided Volume Per Micturition.

Change From Baseline in OAB-q: Health Related Quality of Life (HRQL) at Week 12 (End of Treatment).

Change From Baseline in Patient Perception of Bladder Condition (PPBC).

Change From Baseline in Urgency Perception Scale (UPS). UPS Equals Patient Perception of Urgency Scale (PPUS) in Protocol.

Diary Dry Rates

Frequency of Voids at 12 Weeks

Subjective Patient Change in Irritative Symptoms as Indicated by the Patient Global Impression of Improvement (PGI-I)

Subjective Patient Change in Irritative Urinary Symptoms As Measured By the 3-Day Voiding Diary

Evaluate Subjective Patient Change in Irritative Urinary Symptoms as Measured by the Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score

Subjective Patient Change in Irritative Urinary Symptoms as Indicated by the Patient Global Impression of Improvement (PGI-I)

Subjective Patient Change in Irritative Urinary Symptoms as Indicated by the Patient Satisfaction Questionnaire (PSQ)

Subjective Patient Change in Irritative Urinary Symptoms as Indicated by the Patient Satisfaction Questionnaire (PSQ)

Evaluate Subjective Patient Change in Irritative Urinary Symptoms

Subjective Patient Change in Irritative Urinary Symptoms

Evaluate Subjective Patient Change in Irritative Urinary Symptoms as Measured by the Health Related Quality of Life (HRQL)

Subjective Patient Change in Irritative Urinary Symptoms

Subjective Patient Change in Irritative Urinary Symptoms

Subjective Patient Change in Irritative Urinary Symptoms

Subjective Patient Change in Irritative Urinary Symptoms

Percent Change From Baseline of UUI Episodes Per 24 Hours

Post-hoc Adverse Events (AEs)

Percent Change From Baseline of Severe Urgency Episodes Per 24 Hours

Change From Baseline in Mean Number of Urgency Urinary Episodes Per 24 Hours (Urinary Sensation Scale ≥3 in the Diary)

Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12

Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score at Week 12

Change From Baseline in Frequency-Urgency Sum (FUS) Per 24 Hours (Synonymous With USS Sum in the Study Protocol)

Change From Baseline in Mean Number of Micturitions Per 24 Hours

Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours

Change From Baseline in Mean Number of Severe Urgency Episodes Per 24 Hours

Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 1 and Week 4

Change From Baseline in Mean Urinary Sensation Scale (USS) Rating Per Micturition Per 24 Hours.

Change From Baseline in Mean Voided Volume Per Micturition

Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Health Related Quality of Life (HRQL) at Week 12

Change From Baseline in Patient Perception of Bladder Condition (PPBC)

Change From Baseline in Urgency Perception Scale (UPS). UPS Formerly Known as Patient Perception of Urgency Scale (PPUS) in the Protocol.

Diary Dry Rate: Percentage of Participants With no Urgency Urinary Incontinence (UUI) in the 3-day Bladder Diary

Percent Change From Baseline in Mean Number of Urgency Urinary Episodes Per 24 Hours (Urinary Sensation Scale ≥3 in the Diary)

Percent Change From Baseline of Micturitions Per 24 Hours

Percent Change From Baseline of Nocturnal Micturitions Per 24 Hours

Change From Baseline to Final Visit in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score

Intervention	units on a scale (Mean)
Group 1: Extended Release Tolterodine + Intravaginal Estradiol	-25.4
Group 2: Intravaginal Estradiol Cream + Tolterodine	-28.7

Intervention	percent change (Median)
	Week 1 (n=442, 911, 899)	Week 4 [LOCF] (n=448, 922, 908)	Week 12 [LOCF] (n=448, 926, 908)
Fesoterodine	-50.0	-100.0	-100.0
Placebo	-40.8	-75.0	-100.0
Tolterodine ER	-50.0	-88.9	-100.0

Intervention	events (Number)
	Constipation	Fingers tingling	Finger numbness	Hypertension	Diabetes mellitus	Abdominal distension and discomfort	Tina pedis	Tingling sensation/decreased sensation of fingers	Dyspepsia	Abdominal bloating
Fesoterodine	0	1	1	2	2	1	1	1	1	1
Tolterodine ER	1	0	0	0	0	0	0	0	0	0

Intervention	percent change (Median)
	Week 1 (n=446, 915, 902)	Week 4 [LOCF] (n=452, 926, 911)	Week 12 [LOCF] (n=452, 930, 911)
Fesoterodine	-25.0	-61.1	-79.3
Placebo	-19.7	-41.7	-61.0
Tolterodine ER	-24.1	-55.6	-69.2

Intervention	episodes per 24 hours (Least Squares Mean)
	Week 1 (n=447, 918, 906)	Week 4 [LOCF] (n=453, 929, 915)	Week 12 [LOCF] (n=453, 933, 915)
Fesoterodine	-1.2	-3.1	-4.2
Placebo	-0.8	-1.9	-3.2
Tolterodine ER	-1.0	-2.5	-3.5

Intervention	micturitions per 24 hours (Least Squares Mean)
	Week 1 (n=448, 921, 908)	Week 4 [LOCF] (n=454, 931, 916)	Week 12 [LOCF] (n=454, 935, 916)
Fesoterodine	-1.0	-2.1	-2.6
Placebo	-0.8	-1.5	-2.0
Tolterodine ER	-1.0	-1.8	-2.3

Intervention	nocturnal micturitions per 24 hours (Least Squares Mean)
	Week 1 (n=432, 879, 871)	Week 4 [LOCF] (n=437, 888, 879)	Week 12 [LOCF] (n=437, 892, 879)
Fesoterodine	-0.3	-0.5	-0.7
Placebo	-0.2	-0.4	-0.5
Tolterodine ER	-0.3	-0.5	-0.6

Intervention	mL (Mean)
	Week 1 (n=447, 917, 895)	Week 4 [LOCF] (n=452, 927, 909)	Week 12 [LOCF] (n=452, 930, 912)
Fesoterodine	18.63	32.26	34.47
Placebo	9.80	14.27	17.34
Tolterodine ER	15.65	26.43	28.43

Intervention	scores on a scale (Least Squares Mean)
	HRQL scale score total (n=431, 892, 873)	HRQL concern domain (n=434, 894, 875)	HRQL coping domain (n=433, 892, 875)	HRQL sleep domain (n=433, 894, 875)	HRQL social interaction domain (n=435, 894, 873)
Fesoterodine	22.9	26.8	25.9	21.0	13.9
Placebo	17.2	20.2	19.0	16.6	10.8
Tolterodine ER	19.5	22.5	22.0	18.7	12.0

Intervention	participants (Number)
	Week 1 (n=452, 931, 913) ≥2 points improvement	Week 1: 1-point improvement	Week 1: no change	Week 1: deterioration	Week 4 (n=455, 937, 918) ≥2 points improvement	Week 4: 1-point improvement	Week 4: no change	Week 4: deterioration	Week 12 (n=455, 937, 918) ≥2 points improvement	Week 12: 1-point improvement	Week 12: no change	Week 12: deterioration
Fesoterodine	144	280	428	61	334	280	250	54	440	236	189	53
Placebo	43	144	210	55	111	124	172	48	166	106	133	50
Tolterodine ER	138	278	434	81	290	298	285	64	379	250	249	59